content: <HTML>
  <HEAD>
       <TITLE></TITLE>
  </HEAD>
  <BODY STYLE="font: 10pt Times New Roman, Times, Serif">
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>As filed with the Securities and Exchange Commission
  on June <FONT STYLE="background-color: white">13</FONT>, 2025</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Registration No. 333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM S-8</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REGISTRATION STATEMENT UNDER THE SECURITIES
  ACT OF 1933</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INMUNE BIO INC. </B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR>
      <TD STYLE="border-bottom: black 1.5pt solid; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nevada</B></FONT></TD>
      <TD STYLE="font-size: 10pt">&nbsp;</TD>
      <TD STYLE="border-bottom: black 1.5pt solid; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>47-5205835</B></FONT></TD></TR>
    <TR>
      <TD STYLE="width: 49%">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction of</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">incorporation or organization)</P></TD>
      <TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
      <TD STYLE="width: 49%">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(I.R.S. Employer</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">identification No.)</P></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 3in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white"><B>225 NE
  Mizner Blvd.,&nbsp;Suite 640</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Boca Raton,&nbsp;FL&nbsp;33432</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B>(Address of principal executive offices)
  (Zip Code)</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INmune Bio Inc. 2017 Stock Incentive Plan</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INmune Bio Inc. 2019 Stock Incentive Plan</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Full title of the plan)</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>David Moss</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Chief Financial Officer</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INmune Bio Inc.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white"><B>225 NE
  Mizner Blvd.,&nbsp;Suite 640</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Boca Raton, FL 33432 </B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Name and address of agent for service)</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>(561)&nbsp;710-0512</U></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Telephone number, including area code, of agent
  for service)</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>Copies to:</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Marc Ross, Esq.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Sichenzia Ross Ference Carmel LLP</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>1185 Avenue of the Americas, 31<SUP>st</SUP>
  Floor</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>New York, New York 10036</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Phone: 212- 930-9700</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Fax: 212-930-9725</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
  is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company.
  See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; &ldquo;smaller reporting company,&rdquo;
  and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
    <TR>
      <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer &nbsp;&#9744;</FONT></TD>
      <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer&nbsp; &#9744;</FONT></TD></TR>
    <TR>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated filer&nbsp; &#9746; &nbsp;</FONT></TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company &nbsp;&#9746;</FONT></TD></TR>
    <TR>
      <TD>&nbsp;</TD>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company &nbsp;&#9744;</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
  mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
  standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.&nbsp;&#9744;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  
  <!-- Field: Page; Sequence: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>EXPLANATORY NOTE</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Registration Statement also includes a prospectus
  (the &ldquo;reoffer prospectus&rdquo;) prepared in accordance with General Instruction C of Form S-8 and in accordance with the requirements
  of Part I of Form S-3. This&nbsp;reoffer prospectus&nbsp;for shares granted under the INmune Bio Inc. 2017 Stock Incentive Plan (the &ldquo;2017
  Plan&rdquo;) and INmune Bio Inc. 2019 Stock Incentive Plan (the &ldquo;2019 Plan&rdquo;) may be used for the reoffer and resale of shares
  of common stock on a continuous or delayed basis that may be deemed to be &ldquo;restricted securities&rdquo; and/or &ldquo;control securities&rdquo;
  within the meaning of the&nbsp;Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), and the rules and regulations promulgated
  thereunder, that are issuable to certain of our executive officers, employees, consultants and directors identified in the&nbsp;reoffer
  prospectus. The number of shares of common stock included in the&nbsp;reoffer prospectus&nbsp;represents shares of common stock issuable
  to the selling stockholders pursuant to equity awards, including stock options and restricted stock grants, granted to the selling stockholders
  and does not necessarily represent a present intention to sell any or all such shares of common stock.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
  
  <!-- Field: Page; Sequence: 2 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART I</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Registration Statement relates to two separate
  prospectuses.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Section 10(a) Prospectus</U>: Items 1 and 2,
  from this page, and the documents incorporated by reference pursuant to Part II, Item 3 of this prospectus, constitute a prospectus that
  meets the requirements of Section 10(a) of the Securities Act.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Reoffer Prospectus</U>: The material that follows
  Item 2, up to but not including Part II of this Registration Statement, of which the reoffer prospectus is a part, constitutes a &ldquo;reoffer
  prospectus,&rdquo; prepared in accordance with the requirements of Part I of Form S-3 under the Securities Act. Pursuant to Instruction
  C of Form S-8, the reoffer prospectus may be used for reoffers or resales of shares of common stock which are deemed to be &ldquo;control
  securities&rdquo; or &ldquo;restricted securities&rdquo; under the Securities Act that have been acquired by the selling stockholders
  named in the reoffer prospectus.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 1. Plan Information.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">INmune Bio Inc. will provide each participant
  (the &ldquo;Recipient&rdquo;) with documents that contain information related to the 2017 Plan and 2019 Plan, and other information including,
  but not limited to, the disclosure required by Item 1 of Form S-8, which information is not filed as a part of this Registration Statement
  on Form S-8. The foregoing information and the documents incorporated by reference in response to Item 3 of Part II of this Registration
  Statement taken together constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act. A Section 10(a) prospectus
  will be given to each Recipient who receives shares of common stock covered by this Registration Statement, in accordance with Rule 428(b)(1)
  under the Securities Act.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 2. Registrant Information and Employee Plan Annual Information.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will provide to each Recipient a written statement
  advising it of the availability of documents incorporated by reference in Item 3 of Part II of this Registration Statement and of documents
  required to be delivered pursuant to Rule 428(b) under the Securities Act without charge and upon written or oral notice by contacting:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">INmune Bio Inc.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">225 NE Mizner Blvd., Suite
  640</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Boca Raton, FL 33432</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">Attention: Corporate Secretary</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Telephone: (561) 710-0512</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Information required by Part I to be contained
  in Section 10(a) prospectus is omitted from the Registration Statement in accordance with Rule 428 under the Securities Act.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <!-- Field: Page; Sequence: 3 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>REOFFER PROSPECTUS</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INmune Bio Inc. </B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>3,324,550 Shares of Common Stock</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This reoffer prospectus relates to the aggregate
  sale of 3,324,550 shares of our common stock that may be offered and resold from time to time by the selling stockholders identified in
  this reoffer prospectus for their own account. Such shares have been or may be acquired in connection with 1,592,000 awards granted under
  the 2017 Plan) and 1,732,550 awards granted under the 2019 Plan. It is anticipated that the selling stockholders will offer shares for
  sale at prevailing prices on the Nasdaq Capital Market on the date of sale. We will receive no part of the proceeds from sales made under
  this reoffer prospectus. The selling stockholders will bear all sales commissions and similar expenses. Any other expenses incurred by
  us in connection with the registration and offering and not borne by the selling stockholders will be borne by us.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This reoffer prospectus has been prepared for
  the purposes of registering the shares under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;) to allow for future
  sales by selling stockholders on a continuous or delayed basis to the public without restriction.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The selling stockholders and any brokers executing
  selling orders on their behalf may be deemed to be &ldquo;underwriters&rdquo; within the meaning of the Securities Act, in which event
  commissions received by such brokers may be deemed to be underwriting commissions under the Securities Act.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our common stock is quoted on the Nasdaq Capital
  Market under the symbol &ldquo;INMB.&rdquo; The last reported sale price of our common stock on the Nasdaq Capital Market on June 12,
  2025, was $7.92 per share.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;<B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Investing in our common stock involves a high
  degree of risk. See &ldquo;Risk Factors&rdquo; beginning on page 2 of this reoffer prospectus. </B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Neither the Securities and Exchange Commission
  (the &ldquo;SEC&rdquo;) nor any state securities commission has approved or disapproved of these securities or determined if this reoffer
  prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The date of this reoffer prospectus is June
  13, 2025.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  
  <!-- Field: Page; Sequence: 4 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>TABLE OF CONTENTS </U></B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 90%">&nbsp;</TD>
      <TD STYLE="width: 10%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B>&nbsp;</FONT></TD></TR>
    <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD><A HREF="#a_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cautionary Note Regarding Forward Looking Statements</FONT></A></TD>
      <TD STYLE="text-align: center">ii</TD></TR>
    <TR STYLE="vertical-align: top; background-color: White">
      <TD><A HREF="#a_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prospectus Summary</FONT></A></TD>
      <TD STYLE="text-align: center">1</TD></TR>
    <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD><A HREF="#a_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors</FONT></A></TD>
      <TD STYLE="text-align: center">2</TD></TR>
    <TR STYLE="vertical-align: top; background-color: White">
      <TD><A HREF="#a_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determination of Offering Price </FONT></A></TD>
      <TD STYLE="text-align: center">3</TD></TR>
    <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD><A HREF="#a_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of Proceeds</FONT></A></TD>
      <TD STYLE="text-align: center">3</TD></TR>
    <TR STYLE="vertical-align: top; background-color: White">
      <TD><A HREF="#a_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selling Stockholders</FONT></A></TD>
      <TD STYLE="text-align: center">3</TD></TR>
    <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD><A HREF="#a_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Plan of Distribution</FONT></A></TD>
      <TD STYLE="text-align: center">5</TD></TR>
    <TR STYLE="vertical-align: top; background-color: White">
      <TD><A HREF="#a_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal Matters</FONT></A></TD>
      <TD STYLE="text-align: center">7</TD></TR>
    <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD><A HREF="#a_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Experts</FONT></A></TD>
      <TD STYLE="text-align: center">7</TD></TR>
    <TR STYLE="vertical-align: top; background-color: White">
      <TD><A HREF="#a_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporation of Certain Documents by Reference</FONT></A></TD>
      <TD STYLE="text-align: center">7</TD></TR>
    <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_011">Disclosure of Commission Position on Indemnification For Securities Act Liabilities</A></FONT></TD>
      <TD STYLE="text-align: center">8</TD></TR>
    <TR STYLE="vertical-align: top; background-color: White">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_012">Additional Information Available to You</A></FONT></TD>
      <TD STYLE="text-align: center">8</TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NO PERSON HAS BEEN AUTHORIZED TO GIVE ANY INFORMATION
  OR TO MAKE ANY REPRESENTATIONS, OTHER THAN THOSE CONTAINED IN THIS REOFFER PROSPECTUS, IN CONNECTION WITH THE OFFERING MADE HEREBY, AND,
  IF GIVEN OR MADE, SUCH INFORMATION OR REPRESENTATION MUST NOT BE RELIED UPON AS HAVING BEEN AUTHORIZED BY THE COMPANY OR ANY OTHER PERSON.
  NEITHER THE DELIVERY OF THIS REOFFER PROSPECTUS NOR ANY SALE MADE HEREUNDER SHALL UNDER ANY CIRCUMSTANCES CREATE ANY IMPLICATION THAT
  THERE HAS BEEN NO CHANGE IN THE AFFAIRS OF THE COMPANY SINCE THE DATE HEREOF. THIS REOFFER PROSPECTUS DOES NOT CONSTITUTE AN OFFER TO
  SELL OR A SOLICITATION OF AN OFFER TO BUY ANY SECURITIES OFFERED HEREBY BY ANYONE IN ANY JURISDICTION IN WHICH SUCH OFFER OR SOLICITATION
  IS NOT AUTHORIZED OR IN WHICH THE PERSON MAKING SUCH OFFER OR SOLICITATION IS NOT QUALIFIED TO DO SO OR TO ANY PERSON TO WHOM IT IS UNLAWFUL
  TO MAKE SUCH OFFER OR SOLICITATION.&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
  
  <!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_001"></A>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Some of the statements made under &ldquo;Prospectus Summary,&rdquo;
  &ldquo;Risk Factors,&rdquo; and elsewhere in this reoffer prospectus, as well as the documents incorporated by reference herein, including
  in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, constitute forward-looking statements. In some cases, you
  can identify forward-looking statements by terminology such as &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;should,&rdquo; &ldquo;expects,&rdquo;
  &ldquo;plans,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;believes,&rdquo; &ldquo;estimates,&rdquo; &ldquo;predicts,&rdquo; &ldquo;potential,&rdquo;
  &ldquo;intends,&rdquo; or &ldquo;continue,&rdquo; or the negative of these terms or other comparable terminology.</P>
  
  <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These forward-looking statements may include, but are not limited to,
  statements related to our expected business, new product introductions, results of clinical studies, expectations regarding regulatory
  clearance and the timing of U.S. Food and Drug Administration (&ldquo;FDA&rdquo;) or non-U.S. filings or approvals including meetings
  with FDA or non-U.S. regulatory bodies, our ability to raise funds for general corporate purposes and operations, including our research
  activities and clinical trials, procedures and procedure adoption, future results of operations, future financial position, our ability
  to generate revenues, our financing plans and future capital requirements, anticipated costs of revenue, anticipated expenses, the effect
  of recent accounting pronouncements, our anticipated cash flows, our ability to finance operations from cash flows or otherwise, and statements
  based on current expectations, estimates, forecasts, and projections about the economies and markets in which we operate and intend to
  operate and our beliefs and assumptions regarding these economies and markets.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">Forward-looking statements are not guarantees of future performance
  and are subject to risks and uncertainties. We have based these forward-looking statements on assumptions and assessments made by our
  management in light of their experience and their perception of historical trends, current conditions, expected future developments, and
  other factors they believe to be appropriate.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">Important factors that could cause actual results, developments and
  business decisions to differ materially from those anticipated in these forward-looking statements include, among others, those factors
  referred to in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which is incorporated by reference herein.</P>
  
  <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These statements are only current predictions and are subject to known
  and unknown risks, uncertainties, and other factors that may cause our or our industry&rsquo;s actual results, levels of activity, performance,
  or achievements to be materially different from those anticipated by the forward-looking statements. We discuss many of these risks in
  the documents incorporated by reference herein. You should not rely upon forward-looking statements as predictions of future events.</P>
  
  <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Although we believe that the expectations reflected in the forward-looking
  statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements. Except as required by
  law, we are under no duty to update or revise any of the forward-looking statements, whether as a result of new information, future events
  or otherwise, after the date of this reoffer prospectus.&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
  
  <!-- Field: Page; Sequence: 6; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <DIV STYLE="padding: 5.4pt; border: Black 1.5pt solid; width: 98%">
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_002"></A>PROSPECTUS SUMMARY</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>This reoffer prospectus is part of the Registration Statement that
  we filed with the SEC. We have provided to you in this reoffer prospectus a general description of the selling stockholders and the distribution
  of the shares of common stock. To the extent there is a conflict between the information contained in this reoffer prospectus and any
  of our subsequent filings with the SEC, the information in the document having the later date shall modify or supersede the earlier statement.
  </I></P>
  
  <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>As permitted by the rules and regulations of the SEC, the Registration
  Statement of which this reoffer prospectus forms a part includes additional information not contained in this reoffer prospectus. You
  may read the Registration Statement and the other reports we file with the SEC at the SEC&rsquo;s website or at our website as described
  above under the heading &ldquo;Incorporation of Certain Documents by Reference.&rdquo; </I></P>
  
  <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>In this reoffer prospectus, the &ldquo;Company,&rdquo; &ldquo;we,&rdquo;
  &ldquo;us&rdquo; and &ldquo;our&rdquo; refer to INmune Bio Inc. and its subsidiaries.</I></P>
  
  <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Company Overview</B></P>
  
  <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our objective is to develop and commercialize our product candidates
  to treat diseases where the innate immune system is dysfunctional causing or contributing to the patient&rsquo;s disease. Innate immune
  dysfunction can occur for a variety of reasons including genetics, lifestyle, and other factors. However, age plays a significant role
  in the development of immune dysfunction. Innate immune dysfunction can be seen in cancer where natural killer cells are impaired and
  facilitate a tumor&rsquo;s evasion of the immune system and subsequent disease progression. Chronic inflammation is implicated in neurologic
  and metabolic diseases where it impairs the innate immune system. Our primary focus continues to be treatment of cancer with INKmune and
  treatment of Alzheimer&rsquo;s Disease (&ldquo;AD&rdquo;) and Treatment Resistant Depression (&ldquo;TRD&rdquo;) with XPro1595 (&ldquo;XPro&rdquo;).
  We have added CORDStrom, a pooled, human umbilical cord mesenchymal stem cell product to treat recessive dystrophic epidermolysis bullosa
  (&ldquo;RDEB&rdquo;), a pediatric orphan disease caused by mutations in the COL7A1 gene that results in a debilitating disease of skin
  blistering, dysphagia and failure to thrive with chronic wound problems that often results in fatal squamous cell carcinoma.</P>
  
  <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">XPro, targets AD and TRD. XPro for AD has completed Phase I trials
  and a Phase II trial has completed enrollment of patients at clinical sites in the United Kingdom, European Union (&ldquo;EU&rdquo;),
  Australia and Canada. Patients are currently being treated with XPro for early AD as part of that clinical trial. TRD is being prepared
  for Phase II trials. We expect to start a pivotal global registration trial in patients with AD after the results of the Phase II trial
  have been analyzed. The INKmune program is in an open label Phase II trial in metastatic castrate resistant prostate cancer. CORDStrom
  for the treatment of children with RDEB has completed a pivotal blinded randomized cross-over trial. The data will be submitted for a
  marketing authorization by filing a biologics license application with the FDA which is anticipated in the first half of 2026. Afterwards,
  the company intends to file a marketing authorization application in the United Kingdom and EU.</P>
  
  <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Corporate Information </B></P>
  
  <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our principal executive offices are located at 225 NE Mizner Blvd.,
  Suite 640, Boca Raton, Florida 33432. Our telephone number is (561) 710-0512. We maintain an Internet website at www.inmunebio.com. The
  information contained on, connected to or that can be accessed via our website is not part of this reoffer prospectus and should not be
  relied upon in connection with making any decision with respect to an investment in our securities. We are required to file annual, quarterly
  and current reports, proxy statements and other information with the SEC. You may obtain any of the documents filed by us with the SEC
  at no cost from the SEC&rsquo;s website at http://www.sec.gov.</P>
  
  <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About This Offering</B></P>
  
  <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This offering relates to the resale by the selling stockholders of
  up to 1,592,000 and 1,732,550 shares of common stock issued or issuable upon exercise of options issued pursuant to grants made pursuant
  to our 2017 Plan and 2019 Plan, respectively. If, subsequent to the date of this reoffer prospectus, we grant additional shares of common
  stock to the selling stockholders or to other affiliates under the 2017 Plan and 2019 Plan, we may supplement this reoffer prospectus
  to reflect such additional shares to the selling stockholders and/or the names of such affiliates and the number of shares to be reoffered
  by them under the 2017 Plan and 2019 Plan. Subject to the satisfaction of any conditions to vesting of the shares of common stock offered
  hereby pursuant to the terms of the relevant award agreements, the selling stockholders may from time to time sell, transfer or otherwise
  dispose of any or all of the shares of common stock covered by this reoffer prospectus through underwriters or dealers, directly to purchasers
  (or a single purchaser) or through broker-dealers or agents. We will not receive any proceeds from the sale of common stock by the selling
  stockholders. The selling stockholders will bear all sales commissions and similar expenses. We will bear all expenses of registration
  incurred in connection with this offering, including any other expenses incurred by us in connection with the registration and offering
  that are not borne by the selling stockholders.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  </DIV>
  
  <!-- Field: Page; Sequence: 7; Options: NewSection; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_003"></A>RISK FACTORS</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Investing in our securities involves a high degree
  of risk. Before making an investment decision, you should consider carefully the risks, uncertainties and other factors described in our
  most recently filed Annual Report on Form 10-K, our subsequent quarterly reports on Form 10-Q and current reports on Form 8-K that we
  have filed or will file with the SEC.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Our business, prospects,
  financial condition, or operating results could be harmed by any of these risks, as well as other risks not currently known to us or that
  we currently consider immaterial. The trading price of our common stock could decline due to any of these risks, and, as a result, you
  may lose all or part of your investment. The risks we have described also include forward-looking statements, and our actual results may
  differ substantially from those discussed in these forward-looking statements. See &ldquo;<I>Cautionary Note Regarding Forward-Looking
  Statements</I>.&rdquo; &nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>
  
  <!-- Field: Page; Sequence: 8; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B><A NAME="a_004"></A>DETERMINATION OF OFFERING
  PRICE</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The selling stockholders
  will determine at what price they may sell the shares of common stock offered hereby, and such sales may be made at prevailing market
  prices or at privately negotiated prices. See &ldquo;<I>Plan of Distribution</I>&rdquo; below for more information.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_005"></A>USE OF PROCEEDS</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">The shares of common stock offered
  hereby are being registered for the account of the selling stockholders named in this reoffer prospectus. All proceeds from the resale
  of the shares of common stock by the selling stockholders will go to the selling stockholders and we will not receive any proceeds from
  such resale. However, we will receive the cash exercise price if any of the selling stockholders exercise their options for common stock
  on a cash basis. We intend to use the net proceeds, if any, for working capital or general corporate purposes. We have agreed to pay the
  expenses of registration of these shares.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_006"></A>SELLING STOCKHOLDERS </B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">This offering
  relates to the resale by the selling stockholders who have received or acquired, or may hereafter receive or acquire, the shares pursuant
  to the </FONT>2017 Plan and 2019 Plan<FONT STYLE="background-color: white">. The selling stockholders may resell all, a portion, or none
  of the shares of common stock from time to time.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth, based on information
  provided to us by the selling stockholders or known to us, the name of each selling stockholder, the nature of any position, office or
  other material relationship, if any, which the selling stockholder has had, within the past three years, with us or with any of our predecessors
  or affiliates, and the number of shares of our common stock beneficially owned by the selling stockholder before this offering.&nbsp;Except
  as otherwise indicated, the selling stockholders are past or present employees, directors or consultants of the Company. The number of
  shares owned are those beneficially owned, as determined under the rules of the SEC, and the information is not necessarily indicative
  of beneficial ownership for any other purpose.&nbsp;Under these rules, beneficial ownership includes any shares of common stock as to
  which a person has sole or shared voting power or investment power and any shares of common stock which the person has the right to acquire
  within 60 days through the exercise of any option, warrant or right, through conversion of any security or pursuant to the automatic termination
  of a power of attorney or revocation of a trust, discretionary account or similar arrangement. None of the selling stockholders is a broker-dealer
  or an affiliate of a broker-dealer. Percentage of ownership is based on 23,379,796 shares of common stock outstanding on May 31, 2025.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have assumed all shares of common stock reflected
  on the table will be sold from time to time in the offering covered by this reoffer prospectus.&nbsp;Because the selling stockholders
  may offer all or any portion of the shares of common stock listed in the table below, no estimate can be given as to the amount of those
  shares of common stock covered by this reoffer prospectus that will actually be held by the selling stockholders upon the termination
  of the offering. Selling stockholders may choose not to sell any of the shares of common stock registered herein.</P>
  
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <!-- Field: Page; Sequence: 9; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
    <TR STYLE="vertical-align: bottom">
      <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left; vertical-align: top">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
      <TD COLSPAN="6" STYLE="vertical-align: bottom; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Number
  of Shares</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Beneficially Owned Prior<BR>
  
  to Offering (1)</B></P></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; vertical-align: bottom; font-weight: bold; text-align: center">Number of <BR> Shares<BR>
  Being</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</TD>
      <TD COLSPAN="6" STYLE="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Shares <BR> Beneficially Owned After<BR>
   Offering</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom">
      <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold; vertical-align: bottom">Selling Stockholder</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Position</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="white-space: nowrap; vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Percent&nbsp;(%)</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Offered</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Percent&nbsp;(%)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top; width: 19%; text-align: left">Raymond J. Tesi</TD><TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="vertical-align: top; width: 20%; text-align: center">President, CEO and Director</TD><TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">2,730,952</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">11.1</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">729,337</TD><TD STYLE="width: 1%; text-align: left">(2)</TD><TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">2,001,615</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">8.4</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top; text-align: left">David Moss</TD><TD>&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: center">CFO, Treasurer and Secretary</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,422,143</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.9</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">734,337</TD><TD STYLE="text-align: left">(3)</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,687,806</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.1</TD><TD STYLE="text-align: left">%</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top; text-align: left">Mark Lowdell</TD><TD>&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: center">CSO</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,238,396</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.3</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">580,000</TD><TD STYLE="text-align: left">(4)</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,658,396</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.0</TD><TD STYLE="text-align: left">%</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top; text-align: left">Scott Juda</TD><TD>&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: center">Director</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">427,900</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.8</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">231,975</TD><TD STYLE="text-align: left">(5)</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">195,925</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top; text-align: left">Timothy Schroeder</TD><TD>&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: center">Director</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">408,881</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.7</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">231,975</TD><TD STYLE="text-align: left">(6)</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">176,906</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top; text-align: left">J. Kelly Ganjei</TD><TD>&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: center">Director</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">344,487</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.5</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">231,975</TD><TD STYLE="text-align: left">(7)</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">112,512</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top; text-align: left">Marcia Allen</TD><TD>&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: center">Director</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">218,694</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">139,951</TD><TD STYLE="text-align: left">(8)</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">81,850</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
      <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: White">
      <TD STYLE="padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in; vertical-align: top; text-align: left">Named Selling Stockholders</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
      <TD STYLE="padding-bottom: 1.5pt; vertical-align: top; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,211,346</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
      <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">5.1</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">445,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">(9)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">766,346</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
      <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">3.2</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD></TR>
    <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
      <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt; vertical-align: top">Total</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
      <TD STYLE="vertical-align: top; text-align: center; padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">10,002,799</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
      <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">3,324,550</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
      <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">6,681,356</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
      <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
    </TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">*</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Less than 1%</FONT></TD></TR>
  
  <TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify">The securities &ldquo;beneficially owned&rdquo; by a person
  are determined in accordance with the definition of &ldquo;beneficial ownership&rdquo; set forth in the rules and regulations promulgated
  under the Exchange Act, and accordingly, may include securities owned by and for, among others, the spouse and/or minor children of an
  individual and any other relative who has the same home as such individual, as well as other securities as to which the individual has
  or shares voting or investment power or which such person has the right to acquire within 60 days of May 31, 2025, pursuant to the exercise
  of options, or otherwise. Beneficial ownership may be disclaimed as to certain of the securities.</TD>
  </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in; text-align: left">(2)</TD><TD STYLE="text-align: justify">Includes: (a) vested options to purchase 400,000 shares of
  common stock exercisable by Mr. Tesi at an exercise price of $7.80 per share pursuant to the 2017 Plan; (b) vested options to purchase
  270,000 shares of common stock exercisable by Mr. Tesi at an exercise price of $3.91 per share pursuant to the 2019 Plan; and (c) vested
  options to purchase 59,337 shares of common stock exercisable by Mr. Tesi at an exercise price of $24.82 per share pursuant to the 2019
  Plan.</TD>
  </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in; text-align: left">(3)</TD><TD STYLE="text-align: justify">Includes: (a) vested options to purchase 400,000 shares of
  common stock exercisable by Mr. Moss at an exercise price of $7.80 per share pursuant to the 2017 Plan; (b) vested options to purchase
  59,337 shares of common stock exercisable by Mr. Moss at an exercise price of $24.82 per share pursuant to the 2017 Plan; and (c) vested
  options to purchase 275,000 shares of common stock exercisable by Mr. Moss at an exercise price of $3.91 per share pursuant to the 2019
  Plan.</TD>
  </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in; text-align: left">(4)</TD><TD STYLE="text-align: justify">Includes: (a) vested options to purchase 400,000 shares of
  common stock exercisable by Mr. Lowdell at an exercise price of $7.80 per share pursuant to the 2017 Plan; and (b) vested options to
  purchase 180,000 shares of common stock exercisable by Mr. Lowdell at an exercise price of $3.91 per share pursuant to the 2019 Plan.</TD>
  </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in; text-align: left">(5)</TD><TD STYLE="text-align: justify">Includes (a) vested options to purchase 108,000 shares of
  common stock exercisable by Mr. Juda at an exercise price of $7.80 per share pursuant to the 2017 Plan; (b) vested options to purchase
  108,000 shares of common stock exercisable by Mr. Juda at an exercise price of $3.91 per share pursuant to the 2019 Plan; and (c) vested
  options to purchase 15,975 shares of common stock exercisable by Mr. Juda at an exercise price of $24.82 per share pursuant to the 2019
  Plan.</TD>
  </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in; text-align: left">(6)</TD><TD STYLE="text-align: justify">Includes: (a) vested options to purchase 108,000 shares of
  common stock exercisable by Mr. Schroeder at an exercise price of $7.80 per share pursuant to the 2017 Plan; (b) vested options to purchase
  108,000 shares of common stock exercisable by Mr. Schroeder at an exercise price of $3.91 per share pursuant to the 2019 Plan; and (c)
  vested options to purchase 15,975 shares of common stock exercisable by Mr. Schroeder at an exercise price of $24.82 per share pursuant
  to the 2019 Plan.</TD>
  </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in; text-align: left">(7)</TD><TD STYLE="text-align: justify">Includes: (a) vested options to purchase 108,000 shares of
  common stock exercisable by Mr. Ganjei at an exercise price of $7.80 per share pursuant to the 2017 Plan; (b) vested options to purchase
  108,000 shares of common stock exercisable by Mr. Ganjei at an exercise price of $3.91 per share pursuant to the 2019 Plan; and (c) vested
  options to purchase 15,975 shares of common stock exercisable by Mr. Ganjei at an exercise price of $24.82 per share pursuant to the
  2019 Plan.</TD>
  </TR>
  <TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in; text-align: left">(8)</TD><TD STYLE="text-align: justify">Includes: (a) vested options to purchase 108,000 shares of common stock exercisable by Mrs. Allen at
                                                      an exercise price of $3.91 per share pursuant to the 2019 Plan; (b) vested options to purchase 15,975 shares of common stock
                                                      exercisable by Mrs. Allen at an exercise price of $24.82 per share pursuant to the 2019 Plan; (c) options to purchase 7,313 shares
                                                      of common stock exercisable by Mrs. Allen at an exercise price of $9.74 per share pursuant to the 2019 Plan of which 5,891 are
                                                      exercisable; and (d) options to purchase 8,663 shares of common stock exercisable by Mrs. Allen at an exercise price of $9.74
                                                      pursuant to the 2017 Plan, of which 6,978 are exercisable.</TD>
  </TR><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="text-align: left">(9)</TD><TD STYLE="text-align: justify">Includes the following 3 named non-affiliate persons, each of whom
  holds at least 1,000&nbsp;Shares of Class A common stock or equity awards issuable for an amount equal to 1% or more of the securities
  issuable pursuant to the Company&rsquo;s 2017 and 2019 Stock Option Plans: Christopher Barnum, Josh Schoonover and Cory Ellspermann.</TD></TR>
       </TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <!-- Field: Page; Sequence: 10; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_007"></A>PLAN OF DISTRIBUTION</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Timing of Sales</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">The selling
  stockholders may offer and sell the shares covered by this reoffer prospectus at various times. The selling stockholders will act independently
  of our company in making decisions with respect to the timing, manner and size of each sale.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To our knowledge, no selling stockholder has any
  agreement or understanding, directly or indirectly, with any person to resell the shares of common stock covered by this reoffer prospectus.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Offering Price</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The sales price offered by the selling stockholders
  to the public may be:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
  market price prevailing at the time of sale;</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 50pt; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
  price related to such prevailing market price; or</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">such
  other price as the selling stockholders determine from time to time.</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Manner of Sale </B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The shares of common stock may be sold by means
  of one or more of the following methods:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
  block trade in which the broker-dealer so engaged will attempt to sell the shares of common stock as agent, but may position and resell
  a portion of the block as principal to facilitate the transaction;</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 50pt; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">purchases
  by a broker-dealer as principal and resale by that broker-dealer for its account pursuant to this reoffer prospectus;</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ordinary
  brokerage transactions in which the broker solicits purchasers;</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">through
  options, swaps or derivatives;</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
  transactions to cover short sales;</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">privately
  negotiated transactions; or</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
  a combination of any of the above methods.</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The selling stockholders may sell their shares
  of common stock directly to purchasers or may use brokers, dealers, underwriters or agents to sell their shares of common stock. Brokers
  or dealers engaged by the selling stockholders may arrange for other brokers or dealers to participate. Brokers or dealers may receive
  commissions, discounts or concessions from the selling stockholders, or, if any such broker-dealer acts as agent for the purchaser of
  shares of common stock, from the purchaser in amounts to be negotiated immediately prior to the sale. The compensation received by brokers
  or dealers may, but is not expected to, exceed that which is customary for the types of transactions involved.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Broker-dealers may agree with a selling stockholder
  to sell a specified number of shares of common stock at a stipulated price per common share, and, to the extent the broker-dealer is unable
  to do so acting as agent for a selling stockholder, to purchase as principal any unsold shares of common stock at the price required to
  fulfill the broker-dealer commitment to the selling stockholder.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>
  
  <!-- Field: Page; Sequence: 11; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Broker-dealers who acquire shares of common stock
  as principal may thereafter resell the shares of common stock from time to time in transactions, which may involve block transactions
  and sales to and through other broker-dealers, including transactions of the nature described above, on the Nasdaq Capital Market or otherwise
  at prices and on terms then prevailing at the time of sale, at prices then related to the then-current market price or in negotiated transactions.
  In connection with resales of the shares of common stock, broker-dealers may pay to or receive from the purchasers of shares commissions
  as described above.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the selling stockholders enter into arrangements
  with brokers or dealers, as described above, we are obligated to file a post-effective amendment to this registration statement disclosing
  such arrangements, including the names of any broker-dealers acting as underwriters.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The selling stockholders and any broker-dealers
  or agents that participate with the selling stockholders in the sale of the shares of common stock may be deemed to be &ldquo;underwriters&rdquo;
  within the meaning of the Securities Act. In that event, any commissions received by broker-dealers or agents and any profit on the resale
  of the shares of common stock purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Sales Pursuant to Rule 144</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any shares of common stock covered by this reoffer
  prospectus which qualify for sale pursuant to Rule 144 under the Securities Act may be sold under Rule 144 rather than pursuant to this
  reoffer prospectus.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Regulation&nbsp;M</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The selling stockholders must comply with the
  requirements of the Securities Act and the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;) in the offer and
  sale of the common stock. In particular we will advise the selling stockholders that the anti-manipulation rules of Regulation&nbsp;M
  under the Exchange Act may apply to sales of shares of common stock in the market and to the activities of the selling stockholders and
  their affiliates. Regulation&nbsp;M under the Exchange Act prohibits, with certain exceptions, participants in a distribution from bidding
  for, or purchasing for an account in which the participant has a beneficial interest, any of the securities that are the subject of the
  distribution.&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accordingly, during such times as a selling stockholder
  may be deemed to be engaged in a distribution of the common stock, and therefore be considered to be an underwriter, the selling stockholder
  must comply with applicable law and, among other things:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 24px">&nbsp;</TD>
      <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">may not engage in any stabilization activities in connection with our common stock;</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 24px">&nbsp;</TD>
      <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">may not cover short sales by purchasing shares while the distribution is taking place; and</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 24px">&nbsp;</TD>
      <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">may not bid for or purchase any of our securities or attempt to induce any person to purchase any of our securities other than as permitted under the Exchange Act.</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, we will make copies of this reoffer
  prospectus available to the selling stockholders for the purpose of satisfying the reoffer prospectus delivery requirements of the Securities
  Act.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>State Securities Laws</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the securities laws of some states, the
  shares of common stock may be sold in such states only through registered or licensed brokers or dealers. In addition, in some states
  the shares of common stock may not be sold unless the shares have been registered or qualified for sale in the state or an exemption from
  registration or qualification is available and is complied with.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Expenses of Registration</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are bearing all costs relating to the registration
  of the common stock. The selling stockholders, however, will pay any commissions or other fees payable to brokers or dealers in connection
  with any sale of the common stock.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
  
  <!-- Field: Page; Sequence: 12; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_008"></A>LEGAL MATTERS</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The validity of the common stock has been passed
  upon by Sichenzia Ross Ference Carmel LLP, New York, New York.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_009"></A>EXPERTS</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consolidated financial statements of INmune
  Bio Inc. as of and for the years ended December 31, 2024 and 2023 appearing in INmune Bio Inc.&rsquo;s Annual Report on Form 10-K for
  the year ended December 31, 2024, have been audited by Marcum LLP, as set forth in its report thereon, included therein, and incorporated
  herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance upon such report given on
  the authority of such firm as experts in accounting and auditing.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_010"></A>INCORPORATION
  OF CERTAIN DOCUMENTS by Reference</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The SEC, allows us to incorporate by reference
  certain of our publicly filed documents into this reoffer prospectus, which means that such information is considered part of this reoffer
  prospectus. Information that we file with the SEC subsequent to the date of this reoffer prospectus will automatically update and supersede
  this information. We incorporate by reference the documents listed below and any future filings made with the SEC under all documents
  subsequently filed by us pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act until the selling stockholders have sold all
  of the shares offered hereby or such shares have been deregistered.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
  Annual Report on </FONT><A HREF="https://www.sec.gov/Archives/edgar/data/1711754/000101376225003354/ea0229965-10k_inmune.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
  10-K</FONT></A> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">for the year ended December 31, 2024, filed
  with the SEC on March 27, 2025;</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
  Quarterly Report on </FONT><A HREF="https://www.sec.gov/Archives/edgar/data/1711754/000121390025041072/ea0239166-10q_inmune.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
  10-Q</FONT></A> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">for the quarter ended March 31, 2025, filed
  with the SEC on </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
  8, 2025</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">;</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
  Definitive Proxy Statement on Schedule 14A filed with the SEC on </FONT><A HREF="https://www.sec.gov/Archives/edgar/data/1711754/000121390025033742/ea0237268-01.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
  21, 2025</FONT></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">, as supplemented on </FONT><A HREF="https://www.sec.gov/Archives/edgar/data/1711754/000121390025035538/ea0239501-defa14a_inmune.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
  25, 2025</FONT></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">, and as amended on </FONT><A HREF="https://www.sec.gov/Archives/edgar/data/1711754/000121390025041516/ea0241465-defr14a_inmune.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
  9, 2025</FONT></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">, respectively;</FONT></TD>
  </TR></TABLE>
  
  <P STYLE="margin: 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
  Current Reports on Form 8-K (other than information furnished rather than filed) filed with the SEC on </FONT><A HREF="https://www.sec.gov/Archives/edgar/data/1711754/000121390025007521/ea0228960-8k_inmunebio.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
  28, 2025</FONT></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">, </FONT><A HREF="https://www.sec.gov/Archives/edgar/data/1711754/000121390025011733/ea0230277-8k_inmune.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
  10, 2025</FONT></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">, </FONT><A HREF="https://www.sec.gov/Archives/edgar/data/1711754/000121390025012870/ea0230833-8k_inmune.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
  12, 2025</FONT></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">, </FONT><A HREF="https://www.sec.gov/Archives/edgar/data/1711754/000101376225001309/ea0234771-8k_inmune.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
  24, 2025</FONT></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">, </FONT><A HREF="https://www.sec.gov/Archives/edgar/data/1711754/000121390025027106/ea0236644-8k_inmune.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
  1, 2025</FONT></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">, </FONT><A HREF="https://www.sec.gov/Archives/edgar/data/1711754/000121390025031590/ea0238180-8k_inmune.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
  14, 2025</FONT></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">, </FONT><A HREF="https://www.sec.gov/Archives/edgar/data/1711754/000121390025039733/ea0240883-8k_inmune.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
  5, 2025</FONT></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">, </FONT><A HREF="https://www.sec.gov/Archives/edgar/data/1711754/000121390025040727/ea0241210-8k_inmune.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
  7, 2025,</FONT></A> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT><A HREF="https://www.sec.gov/Archives/edgar/data/1711754/000121390025043270/ea0242053-8k_inmune.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
  14, 2025</FONT></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> and <A HREF="https://www.sec.gov/Archives/edgar/data/1711754/000121390025053051/ea0245174-8k_inmune.htm">June 10, 2025</A> and </FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
  description of our common stock contained in our Registration Statement on </FONT><A HREF="http://www.sec.gov/Archives/edgar/data/1711754/000164033419000136/inmune_8a12b.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
  8-A</FONT></A> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">filed with the SEC on February&nbsp;1, 2019 (File
  No. 001-38793), including any amendment or report filed for the purpose of updating such description. In addition, a </FONT><A HREF="http://www.sec.gov/Archives/edgar/data/1711754/000121390020045474/ea132342-8a12b_inmune.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
  8-A</FONT></A> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">filed on December 30, 2020, contains a description
  of certain rights attributable to the common stock.</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Notwithstanding the foregoing, information furnished
  under Items 2.02 and 7.01 of any Current Report on Form 8-K, including the related exhibits, is not incorporated by reference in this
  Registration Statement. The information about us contained in this reoffer prospectus should be read together with the information in
  the documents incorporated by reference. You may request a copy of any or all of these filings, at no cost, by writing or telephoning
  us at: David Moss, INmune Bio Inc., 225 NE Mizner Blvd, Suite 640, Boca Raton, Florida 33432, telephone number (561) 710-0512.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <!-- Field: Page; Sequence: 13; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="a_011"></A>Disclosure Of Commission Position On Indemnification For
  Securities Act Liabilities</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NRS 78.7502(1) provides that a corporation may
  indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or
  proceeding, whether civil, criminal, administrative or investigative, except an action by or in the right of the corporation, by reason
  of the fact that he is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation
  as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses,
  including attorneys&rsquo; fees, judgments, fines and amounts paid in settlement actually and reasonably incurred by him in connection
  with the action, suit or proceeding if he: (a) is not liable pursuant to NRS 78.138; or (b) acted in good faith and in a manner which
  he reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding,
  had no reasonable cause to believe his conduct was unlawful.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NRS Section 78.7502(2) provides that a corporation
  may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit
  by or in the right of the corporation to procure a judgment in its favor by reason of the fact that he is or was a director, officer,
  employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent
  of another corporation, partnership, joint venture, trust or other enterprise against expenses, including amounts paid in settlement and
  attorneys&rsquo; fees actually and reasonably incurred by him in connection with the defense or settlement of the action or suit if he:
  (a) is not liable pursuant to NRS 78.138; or (b) acted in good faith and in a manner which he reasonably believed to be in or not opposed
  to the best interests of the corporation. Indemnification may not be made for any claim, issue or matter as to which such a person has
  been adjudged by a court of competent jurisdiction, after exhaustion of all appeals there from, to be liable to the corporation or for
  amounts paid in settlement to the corporation, unless and only to the extent that the court in which the action or suit was brought or
  other court of competent jurisdiction determines upon application that in view of all the circumstances of the case, the person is fairly
  and reasonably entitled to indemnity for such expenses as the court deems proper.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Articles of Incorporation provides that every
  person who was or is a party to, or is threatened to be made a party to, or is involved in any action, suit or proceeding, whether civil,
  criminal, administrative or investigative, by reason of the fact that he, or a person of whom he is the legal representative, is or was
  a director or officer of the Company, or is or was serving at the request of the Company as a director or officer of another corporation,
  or as its representative in a partnership, joint venture, trust or other enterprise, shall be indemnified and held harmless to the fullest
  extent legally permissible under the laws of the State of Nevada from time to time against all expenses, liability and loss (including
  attorney&rsquo;s fees, judgements, fines and amounts paid or to be paid in settlement) reasonably incurred or suffered by him in connection
  therewith. Such right of indemnification shall be a contract right which may be enforced in any matter desired by such person. The expenses
  of the officers and directors incurred in defending a civil or criminal action, suit or proceeding must be paid by the Company as they
  are incurred and in advance of the final disposition of the action, suit or proceeding, upon receipt of an undertaking by or on behalf
  of the director or officer to repay the amount if it is ultimately determined by a court of competent jurisdiction that he is not entitled
  to be indemnified by the Company. Such right of indemnification shall not be exclusive of any other right which such directors, officers
  or representatives may have or hereafter acquire, and, without limiting the generality of such statement, they shall be entitled to their
  respective rights of indemnification under any bylaw, agreement, vote of stockholders, provision of law, or otherwise, as well as their
  rights under this Article.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NRS Section 78.747 provides that except as otherwise
  provided by specific statute, no director or officer of a corporation is individually liable for a debt or liability of the corporation,
  unless the director or officer acts as the alter ego of the corporation. The court as a matter of law must determine the question of whether
  a director or officer acts as the alter ego of a corporation.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Insofar as indemnification for liabilities arising
  under the Securities Act may be permitted to directors, offices or controlling persons of ours, pursuant to the foregoing provisions,
  or otherwise, we have been advised that, in the opinion of the Securities and Exchange Commission, such indemnification is against public
  policy as expressed in the Securities Act, and is, therefore, unenforceable. In the event that a claim for indemnification against such
  liabilities (other than the payment by us of expenses incurred or paid by a director, officer or controlling person of ours in the successful
  defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities
  being registered hereunder, we will, unless in the opinion of our counsel the matter has been settled by controlling precedent, submit
  to a court of appropriate jurisdiction the question whether such indemnification by us is against public policy as expressed in the Securities
  Act and will be governed by the final adjudication of such issue.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><A NAME="a_012"></A>Additional Information Available to You</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus is part of a Registration Statement
  on Form S-8 that we filed with the SEC. Certain information in the Registration Statement has been omitted from this prospectus in accordance
  with the rules of the SEC. We file annual, quarterly and special reports, proxy statements and other information with the SEC. You can
  inspect and copy the Registration Statement as well as reports, proxy statements and other information we have filed with the SEC at the
  public reference room maintained by the SEC at 100 F Street N.E. Washington, D.C. 20549, You can obtain copies from the public reference
  room of the SEC at 100 F Street N.E. Washington, D.C. 20549, upon payment of certain fees. You can call the SEC at 1-800-732-0330 for
  further information about the public reference room. We are also required to file electronic versions of these documents with the SEC,
  which may be accessed through the SEC&rsquo;s World Wide Web site at http://www.sec.gov. No dealer, salesperson or other person is authorized
  to give any information or to make any representations other than those contained in this prospectus, and, if given or made, such information
  or representations must not be relied upon as having been authorized by us. This prospectus does not constitute an offer to buy any security
  other than the securities offered by this prospectus, or an offer to sell or a solicitation of an offer to buy any securities by any person
  in any jurisdiction where such offer or solicitation is not authorized or is unlawful. Neither delivery of this prospectus nor any sale
  hereunder shall, under any circumstances, create any implication that there has been no change in the affairs of our company since the
  date hereof.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <!-- Field: Page; Sequence: 14; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART II </B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
  </B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 3. Incorporation of Documents by Reference.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Securities and Exchange Commission, or SEC,
  allows us to incorporate by reference certain of our publicly filed documents into this prospectus, which means that such information
  is considered part of this prospectus. Information that we file with the SEC subsequent to the date of this prospectus will automatically
  update and supersede this information. We incorporate by reference the documents listed below and any future filings made with the SEC
  under all documents subsequently filed by us pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act until the selling stockholders
  have sold all of the shares offered hereby or such shares have been deregistered.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
  Annual Report on </FONT><A HREF="https://www.sec.gov/Archives/edgar/data/1711754/000101376225003354/ea0229965-10k_inmune.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
  10-K</FONT></A> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">for the year ended December 31, 2024, filed
  with the SEC on March 27, 2025;</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
  Quarterly Report on </FONT><A HREF="https://www.sec.gov/Archives/edgar/data/1711754/000121390025041072/ea0239166-10q_inmune.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
  10-Q</FONT></A> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">for the quarter ended March 31, 2025, filed
  with the SEC on </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
  8, 2025</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">;</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
  Definitive Proxy Statement on Schedule 14A filed with the SEC on </FONT><A HREF="https://www.sec.gov/Archives/edgar/data/1711754/000121390025033742/ea0237268-01.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
  21, 2025</FONT></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">, as supplemented on </FONT><A HREF="https://www.sec.gov/Archives/edgar/data/1711754/000121390025035538/ea0239501-defa14a_inmune.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
  25, 2025</FONT></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">, and as amended on </FONT><A HREF="https://www.sec.gov/Archives/edgar/data/1711754/000121390025041516/ea0241465-defr14a_inmune.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
  9, 2025</FONT></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">, respectively;</FONT></TD>
  </TR></TABLE>
  
  <P STYLE="margin: 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
  Current Reports on Form 8-K (other than information furnished rather than filed) filed with the SEC on </FONT><A HREF="https://www.sec.gov/Archives/edgar/data/1711754/000121390025007521/ea0228960-8k_inmunebio.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
  28, 2025</FONT></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">, </FONT><A HREF="https://www.sec.gov/Archives/edgar/data/1711754/000121390025011733/ea0230277-8k_inmune.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
  10, 2025</FONT></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">, </FONT><A HREF="https://www.sec.gov/Archives/edgar/data/1711754/000121390025012870/ea0230833-8k_inmune.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
  12, 2025</FONT></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">, </FONT><A HREF="https://www.sec.gov/Archives/edgar/data/1711754/000101376225001309/ea0234771-8k_inmune.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
  24, 2025</FONT></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">, </FONT><A HREF="https://www.sec.gov/Archives/edgar/data/1711754/000121390025027106/ea0236644-8k_inmune.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
  1, 2025</FONT></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">, </FONT><A HREF="https://www.sec.gov/Archives/edgar/data/1711754/000121390025031590/ea0238180-8k_inmune.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
  14, 2025</FONT></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">, </FONT><A HREF="https://www.sec.gov/Archives/edgar/data/1711754/000121390025039733/ea0240883-8k_inmune.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
  5, 2025</FONT></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">, </FONT><A HREF="https://www.sec.gov/Archives/edgar/data/1711754/000121390025040727/ea0241210-8k_inmune.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
  7, 2025,</FONT></A> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT><A HREF="https://www.sec.gov/Archives/edgar/data/1711754/000121390025043270/ea0242053-8k_inmune.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May
  14, 2025</FONT></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> and <A HREF="https://www.sec.gov/Archives/edgar/data/1711754/000121390025053051/ea0245174-8k_inmune.htm">June 10, 2025</A> and</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
  description of our common stock contained in our Registration Statement on </FONT><A HREF="http://www.sec.gov/Archives/edgar/data/1711754/000164033419000136/inmune_8a12b.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
  8-A</FONT></A> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">filed with the SEC on February&nbsp;1, 2019 (File
  No. 001-38793), including any amendment or report filed for the purpose of updating such description. In addition, a </FONT><A HREF="http://www.sec.gov/Archives/edgar/data/1711754/000121390020045474/ea132342-8a12b_inmune.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
  8-A</FONT></A> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">filed on December 30, 2020, contains a description
  of certain rights attributable to the common stock.</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Notwithstanding the foregoing, information furnished under Items 2.02
  and 7.01 of any Current Report on Form 8-K, including the related exhibits, is not incorporated by reference in this Registration Statement.
  The information about us contained in this reoffer prospectus should be read together with the information in the documents incorporated
  by reference. You may request a copy of any or all of these filings, at no cost, by writing or telephoning us at: David Moss, INmune Bio
  Inc., 225 NE Mizner Blvd, Suite 640, Boca Raton, Florida 33432, telephone number (561) 710-0512.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 4. Description of Securities.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not applicable.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 5. Interests of Named Experts and Counsel.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">None.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 6. Indemnification of Directors and Officers.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">Section 78.7502(1) of the Nevada Revised Statutes (&ldquo;NRS&rdquo;)
  provides that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending
  or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, except an action by or in the right
  of the corporation, by reason of the fact that he is or was a director, officer, employee or agent of the corporation, or is or was serving
  at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust
  or other enterprise, against expenses, including attorneys&rsquo; fees, judgments, fines and amounts paid in settlement actually and reasonably
  incurred by him in connection with the action, suit or proceeding if he: (a) is not liable pursuant to NRS 78.138; or (b) acted in good
  faith and in a manner which he reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect
  to any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <!-- Field: Page; Sequence: 15; Options: NewSection; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">NRS Section 78.7502(2) provides that a corporation may indemnify any
  person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right
  of the corporation to procure a judgment in its favor by reason of the fact that he is or was a director, officer, employee or agent of
  the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation,
  partnership, joint venture, trust or other enterprise against expenses, including amounts paid in settlement and attorneys&rsquo; fees
  actually and reasonably incurred by him in connection with the defense or settlement of the action or suit if he: (a) is not liable pursuant
  to NRS 78.138; or (b) acted in good faith and in a manner which he reasonably believed to be in or not opposed to the best interests of
  the corporation. Indemnification may not be made for any claim, issue or matter as to which such a person has been adjudged by a court
  of competent jurisdiction, after exhaustion of all appeals there from, to be liable to the corporation or for amounts paid in settlement
  to the corporation, unless and only to the extent that the court in which the action or suit was brought or other court of competent jurisdiction
  determines upon application that in view of all the circumstances of the case, the person is fairly and reasonably entitled to indemnity
  for such expenses as the court deems proper.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">Our Articles of Incorporation provides that very person who was or
  is a party to, or is threatened to be made a party to, or is involved in any action, suit or proceeding, whether civil, criminal, administrative
  or investigative, by reason of the fact that he, or a person of whom he is the legal representative, is or was a director or officer of
  the Company, or is or was serving at the request of the Company as a director or officer of another corporation, or as its representative
  in a partnership, joint venture, trust or other enterprise, shall be indemnified and held harmless to the fullest extent legally permissible
  under the laws of the State of Nevada from time to time against all expenses, liability and loss (including attorney&rsquo;s fees, judgements,
  fines and amounts paid or to be paid in settlement) reasonably incurred or suffered by him in connection therewith. Such right of indemnification
  shall be a contract right which may be enforced in any matter desired by such person. The expenses of the officers and directors incurred
  in defending a civil or criminal action, suit or proceeding must be paid by the Company as they are incurred and in advance of the final
  disposition of the action, suit or proceeding, upon receipt of an undertaking by or on behalf of the director or officer to repay the
  amount if it is ultimately determined by a court of competent jurisdiction that he is not entitled to be indemnified by the Company. Such
  right of indemnification shall not be exclusive of any other right which such directors, officers or representatives may have or hereafter
  acquire, and, without limiting the generality of such statement, they shall be entitled to their respective rights of indemnification
  under any bylaw, agreement, vote of stockholders, provision of law, or otherwise, as well as their rights under this Article.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">NRS Section 78.747 provides that except as otherwise provided by specific
  statute, no director or officer of a corporation is individually liable for a debt or liability of the corporation, unless the director
  or officer acts as the alter ego of the corporation. The court as a matter of law must determine the question of whether a director or
  officer acts as the alter ego of a corporation.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">Insofar as indemnification for liabilities arising under the Securities
  Act of 1933, as amended, may be permitted to directors, offices or controlling persons of ours, pursuant to the foregoing provisions,
  or otherwise, we have been advised that, in the opinion of the SEC, such indemnification is against public policy as expressed in the
  Securities Act of 1933, as amended, and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities
  (other than the payment by us of expenses incurred or paid by a director, officer or controlling person of ours in the successful defense
  of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being
  registered hereunder, we will, unless in the opinion of our counsel the matter has been settled by controlling precedent, submit to a
  court of appropriate jurisdiction the question whether such indemnification by us is against public policy as expressed in the Securities
  Act of 1933, as amended, and will be governed by the final adjudication of such issue.&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <!-- Field: Page; Sequence: 16; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 7. Exemption from Registration Claimed.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not applicable.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 8. Exhibits.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR>
      <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: top; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit Number</B></FONT></TD>
      <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
      <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 90%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
    <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1711754/000164033418001703/inmune_ex31.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Articles of Incorporation (Incorporated by reference to Exhibit 3.1 to the Registration Statement on Form S-1 filed with the SEC on August 30, 2018).</FONT></A></TD></TR>
    <TR STYLE="vertical-align: top; background-color: White">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1711754/000164033418001703/inmune_ex32.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bylaws (Incorporated by reference to Exhibit 3.2 to the Registration Statement on Form S-1 filed with the SEC on August 30, 2018).</FONT></A></TD></TR>
    <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1711754/000121390024046252/ea020679101ex3-1_inmune.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">First Amendment to the Bylaws of INmune Bio Inc. (Incorporated by reference to Exhibit 3.1 to the Company&rsquo;s Current Report on Form 8-K filed with the SEC on May 23, 2024).</FONT></A></TD></TR>
    <TR STYLE="vertical-align: top; background-color: White">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="ea024481701ex5-1_inmune.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion of Sichenzia Ross Ference Carmel LLP*</FONT></A></TD></TR>
    <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea024481701ex23-1_inmune.htm">Consent of Marcum LLP*</A></FONT></TD></TR>
    <TR STYLE="vertical-align: top; background-color: White">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="ea024481701ex5-1_inmune.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Sichenzia Ross Ference Carmel LLP (included in Exhibit 5.1)*</FONT></A></TD></TR>
    <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="#poa_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power of Attorney (included on the signature page)*</FONT></A></TD></TR>
    <TR STYLE="vertical-align: top; background-color: White">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1711754/000121390021016974/ea137528ex99-1_inmunebioinc.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INmune Bio Inc. 2017 Stock Incentive Plan (incorporated by reference to the Form S-8 filed with the SEC on March 3, 2022).</FONT></A></TD></TR>
    <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.2</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1711754/000121390021016974/ea137528ex99-2_inmunebioinc.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INmune Bio Inc. 2019 Stock Incentive Plan (incorporated by reference to the Form S-8 filed with the SEC on March 3, 2022).</FONT></A></TD></TR>
    <TR STYLE="vertical-align: top; background-color: White">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">107</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1711754/000121390021016974/ea137528-s8_inmunebioinc.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filing Fee Table*</FONT></A></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in; text-align: left">*</TD><TD STYLE="text-align: justify">Filed herewith.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in; text-align: left">**</TD><TD STYLE="text-align: justify">Previously Filed.</TD>
  </TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 9. Undertakings.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
  Company hereby undertakes:</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
  file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
  include any prospectus required by Section&nbsp;10(a)(3) of the Securities Act.</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
  reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective
  amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration
  Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities
  offered&nbsp;&nbsp;would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering
  range may be reflected in the form of prospectus filed with the Securities and Exchange Commission pursuant to Rule 424(b) if, in the
  aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth
  in the &ldquo;Calculation of Registration Fee&rdquo; table in the effective Registration Statement.</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;&nbsp;&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
  include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any
  material change to such information in the Registration Statement; provided, however, that (A)&nbsp;paragraphs (a)(1)(i) and (a)(1)(ii)
  of this section do not apply if the Registration Statement is on Form S&ndash;8 (&sect;239.16b of Regulation S-K), and the information
  required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Securities
  and Exchange Commission by the Company pursuant to section 13 or section 15(d) of the Exchange Act (15 U.S.C. 78m or 78o(d)) that are
  incorporated by reference in the Registration Statement; and (B)&nbsp;paragraphs (a)(1)(i), (a)(1)(ii) and (a)(1)(iii) do not apply if
  the Registration Statement is on Form S-3 or Form F-3, and the information required to be included in a post-effective amendment by those
  paragraphs is contained in reports filed with or furnished to the Securities and Exchange Commission by the Company pursuant to Section&nbsp;13
  or Section&nbsp;15(d) of the Exchange Act that are incorporated by reference in the Registration Statement, or is contained in a form
  of prospectus filed pursuant to Rule 424(b) that is part of the Registration Statement; provided further, however, that paragraphs (a)(1)(i)
  and (a)(1)(ii) do not apply if the Registration Statement is for an offering of asset-backed securities on Form S-1 or Form S-3, and
  the information required to be included in a post-effective amendment is provided pursuant to Item&nbsp;1100(c) of Regulation AB.</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>
  
  <!-- Field: Page; Sequence: 17; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">That,
  for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new
  registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to
  be the initial bona fide offering thereof.</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
  remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination
  of the offering.</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">That,
  for the purpose of determining liability under the Securities Act of 1933 to any purchaser:</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(A)&nbsp;Each prospectus filed
  by a Registrant pursuant to Rule&nbsp;424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus
  was deemed part of and included in the registration statement; and</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(B)&nbsp;Each prospectus required
  to be filed pursuant to Rule&nbsp;424(b)(2), (b)(5) or (b)(7) as part of a registration statement in reliance on Rule&nbsp;430B relating
  to an offering made pursuant to Rule&nbsp;415(a)(1)(i),&nbsp;&nbsp;(vii)&nbsp;or (x)&nbsp;for the purpose of providing the information
  required by Section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement as of
  the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities
  in the offering described in the prospectus. As provided in Rule&nbsp;430B, for liability purposes of the issuer and any person that is
  at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities
  in the registration statement to which the prospectus relates, and the offering of such securities at that time shall be deemed to be
  the initial bona fide offering thereof. Provided, however, that no statement made in a registration statement or prospectus that is part
  of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or
  prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective
  date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement
  or made in any such document immediately prior to such effective date.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
  Company hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Company&rsquo;s
  annual report pursuant to Section&nbsp;13(a) or Section&nbsp;15(d) of the Exchange Act that is incorporated by reference in this Registration
  Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities
  at that time shall be deemed to be the initial bona fide offering thereof.</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
  <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insofar
  as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of
  the Company pursuant to the foregoing provisions, or otherwise, the Company has been advised that in the opinion of the Securities and
  Exchange Commission such indemnification is against public policy as expressed in the Securities Act, and is, therefore, unenforceable.
  In the event that a claim for indemnification against such liabilities (other than the payment by the Company of expenses incurred or
  paid by a director, officer or controlling person of the Company in the successful defense of any action, suit or proceeding) is asserted
  by such director, officer or controlling person in connection with the securities being registered, the Company will, unless in the opinion
  of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether
  such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication
  of such issue.</FONT></TD>
  </TR></TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  
  <!-- Field: Page; Sequence: 18; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">Pursuant
  to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that
  it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by
  the undersigned, thereunto duly authorized, in the City of Boca Raton, State of Florida, on June 13, 2025.</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 60%">&nbsp;</TD>
      <TD STYLE="width: 40%">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>INmune Bio Inc. </B></P></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Raymond J. Tesi</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Raymond J. Tesi, M. D. </FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer)</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ David J. Moss</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David J. Moss</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Financial and Accounting Officer)</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
  
  
  <!-- Field: Page; Sequence: 19; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><A NAME="poa_001"></A>Each person whose signature
  appears below constitutes and appoints Raymond J. Tesi and David J. Moss, and each of them severally, as his true and lawful attorney
  in fact and agent, with full powers of substitution and re-substitution, for him and in his name, place and stead, in any and all capacities,
  to sign any or all amendments (including post effective amendments) to the Registration Statement, and to sign any registration statement
  for the same offering covered by this Registration Statement that is to be effective upon filing pursuant to Rule 462(b) under the Securities
  Act of 1933, as amended, and all post effective amendments thereto, and to file the same, with all exhibits thereto, and all documents
  in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent, each acting alone,
  full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises,
  as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact
  and agent, each acting alone, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
  of the Securities Act of 1933, as amended, this registration statement has been signed below by the following persons in the capacities
  and on the dates indicated.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: black 1.5pt solid; width: 40%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Raymond J. Tesi</FONT></TD>
      <TD STYLE="width: 35%; text-align: justify">&nbsp;</TD>
      <TD STYLE="width: 25%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 13, 2025</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Raymond J. Tesi, M.D. </FONT></TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer and&nbsp;Director<BR>
  (principal executive officer)</FONT></TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ David J. Moss</FONT></TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 13, 2025</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David J. Moss</FONT></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Financial Officer</P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(principal financial and accounting officer)</P></TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Timothy Schroeder</FONT></TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 13, 2025</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Timothy Schroeder</FONT></TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ J. Kelly Ganjei</FONT></TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 13, 2025</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">J. Kelly Ganjei </FONT></TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Scott Juda</FONT></TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 13, 2025</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scott Juda, JD</FONT></TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Marcia Allen</FONT></TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 13, 2025</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marcia Allen</FONT></TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD STYLE="text-align: center">&nbsp;</TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">II-6</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>
  
  
  
  
  </BODY>
  </HTML>
metadata_documents: [{"type": "S-8", "sequence": "1", "filename": "ea0244817-s8_inmune.htm", "description": "REGISTRATION STATEMENT", "secsgml_size_bytes": 169284}]
metadata_filer: {"company-data": {"conformed-name": "Inmune Bio, Inc.", "cik": "0001711754", "assigned-sic": "2836", "organization-name": "03 Life Sciences", "ein": "475205835", "state-of-incorporation": "NV", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-288058", "film-number": "251048150"}, "business-address": {"street1": "225 NE MIZNER BLVD, SUITE 640", "city": "BOCA RATON", "state": "FL", "zip": "33432", "phone": "8589643720"}, "mail-address": {"street1": "225 NE MIZNER BLVD, SUITE 640", "city": "BOCA RATON", "state": "FL", "zip": "33432"}}
text: As filed with the Securities and Exchange Commission
  on June
  13
  , 2025
  Registration No. 333-
  UNITED STATES
  SECURITIES AND EXCHANGE COMMISSION
  Washington, D.C. 20549
  FORM S-8
  REGISTRATION STATEMENT UNDER THE SECURITIES
  ACT OF 1933
  INMUNE BIO INC.
  (Exact name of registrant as specified in its charter)
  Nevada
  47-5205835
  (State or other jurisdiction of
  incorporation or organization)
  (I.R.S. Employer
  identification No.)
  225 NE
  Mizner Blvd., Suite 640
  Boca Raton, FL 33432
  (Address of principal executive offices)
  (Zip Code)
  INmune Bio Inc. 2017 Stock Incentive Plan
  INmune Bio Inc. 2019 Stock Incentive Plan
  (Full title of the plan)
  David Moss
  Chief Financial Officer
  INmune Bio Inc.
  225 NE
  Mizner Blvd., Suite 640
  Boca Raton, FL 33432
  (Name and address of agent for service)
  (561) 710-0512
  (Telephone number, including area code, of agent
  for service)
  Copies to:
  Marc Ross, Esq.
  Sichenzia Ross Ference Carmel LLP
  1185 Avenue of the Americas, 31
  st
  Floor
  New York, New York 10036
  Phone: 212- 930-9700
  Fax: 212-930-9725
  Indicate by check mark whether the registrant
  is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company.
  See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company,"
  and "emerging growth company" in Rule 12b-2 of the Exchange Act.
  Large accelerated filer  ☐
  Accelerated filer  ☐
  Non-accelerated filer  ☒
  Smaller reporting company  ☒
  Emerging growth company  ☐
  If an emerging growth company, indicate by check
  mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
  standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
  EXPLANATORY NOTE
  This Registration Statement also includes a prospectus
  (the "reoffer prospectus") prepared in accordance with General Instruction C of Form S-8 and in accordance with the requirements
  of Part I of Form S-3. This reoffer prospectus for shares granted under the INmune Bio Inc. 2017 Stock Incentive Plan (the "2017
  Plan") and INmune Bio Inc. 2019 Stock Incentive Plan (the "2019 Plan") may be used for the reoffer and resale of shares
  of common stock on a continuous or delayed basis that may be deemed to be "restricted securities" and/or "control securities"
  within the meaning of the Securities Act of 1933, as amended (the "Securities Act"), and the rules and regulations promulgated
  thereunder, that are issuable to certain of our executive officers, employees, consultants and directors identified in the reoffer
  prospectus. The number of shares of common stock included in the reoffer prospectus represents shares of common stock issuable
  to the selling stockholders pursuant to equity awards, including stock options and restricted stock grants, granted to the selling stockholders
  and does not necessarily represent a present intention to sell any or all such shares of common stock.
  PART I
  INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
  This Registration Statement relates to two separate
  prospectuses.
  Section 10(a) Prospectus
  : Items 1 and 2,
  from this page, and the documents incorporated by reference pursuant to Part II, Item 3 of this prospectus, constitute a prospectus that
  meets the requirements of Section 10(a) of the Securities Act.
  Reoffer Prospectus
  : The material that follows
  Item 2, up to but not including Part II of this Registration Statement, of which the reoffer prospectus is a part, constitutes a "reoffer
  prospectus," prepared in accordance with the requirements of Part I of Form S-3 under the Securities Act. Pursuant to Instruction
  C of Form S-8, the reoffer prospectus may be used for reoffers or resales of shares of common stock which are deemed to be "control
  securities" or "restricted securities" under the Securities Act that have been acquired by the selling stockholders
  named in the reoffer prospectus.
  Item 1. Plan Information.
  INmune Bio Inc. will provide each participant
  (the "Recipient") with documents that contain information related to the 2017 Plan and 2019 Plan, and other information including,
  but not limited to, the disclosure required by Item 1 of Form S-8, which information is not filed as a part of this Registration Statement
  on Form S-8. The foregoing information and the documents incorporated by reference in response to Item 3 of Part II of this Registration
  Statement taken together constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act. A Section 10(a) prospectus
  will be given to each Recipient who receives shares of common stock covered by this Registration Statement, in accordance with Rule 428(b)(1)
  under the Securities Act.
  Item 2. Registrant Information and Employee Plan Annual Information.
  We will provide to each Recipient a written statement
  advising it of the availability of documents incorporated by reference in Item 3 of Part II of this Registration Statement and of documents
  required to be delivered pursuant to Rule 428(b) under the Securities Act without charge and upon written or oral notice by contacting:
  INmune Bio Inc.
  225 NE Mizner Blvd., Suite
  640
  Boca Raton, FL 33432
  Attention: Corporate Secretary
  Telephone: (561) 710-0512
  Information required by Part I to be contained
  in Section 10(a) prospectus is omitted from the Registration Statement in accordance with Rule 428 under the Securities Act.
  REOFFER PROSPECTUS
  INmune Bio Inc.
  3,324,550 Shares of Common Stock
  This reoffer prospectus relates to the aggregate
  sale of 3,324,550 shares of our common stock that may be offered and resold from time to time by the selling stockholders identified in
  this reoffer prospectus for their own account. Such shares have been or may be acquired in connection with 1,592,000 awards granted under
  the 2017 Plan) and 1,732,550 awards granted under the 2019 Plan. It is anticipated that the selling stockholders will offer shares for
  sale at prevailing prices on the Nasdaq Capital Market on the date of sale. We will receive no part of the proceeds from sales made under
  this reoffer prospectus. The selling stockholders will bear all sales commissions and similar expenses. Any other expenses incurred by
  us in connection with the registration and offering and not borne by the selling stockholders will be borne by us.
  This reoffer prospectus has been prepared for
  the purposes of registering the shares under the Securities Act of 1933, as amended (the "Securities Act") to allow for future
  sales by selling stockholders on a continuous or delayed basis to the public without restriction.
  The selling stockholders and any brokers executing
  selling orders on their behalf may be deemed to be "underwriters" within the meaning of the Securities Act, in which event
  commissions received by such brokers may be deemed to be underwriting commissions under the Securities Act.
  Our common stock is quoted on the Nasdaq Capital
  Market under the symbol "INMB." The last reported sale price of our common stock on the Nasdaq Capital Market on June 12,
  2025, was $7.92 per share.
  Investing in our common stock involves a high
  degree of risk. See "Risk Factors" beginning on page 2 of this reoffer prospectus.
  Neither the Securities and Exchange Commission
  (the "SEC") nor any state securities commission has approved or disapproved of these securities or determined if this reoffer
  prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
  The date of this reoffer prospectus is June
  13, 2025.
  TABLE OF CONTENTS
  Page
  Cautionary Note Regarding Forward Looking Statements
  ii
  Prospectus Summary
  1
  Risk Factors
  2
  Determination of Offering Price
  3
  Use of Proceeds
  3
  Selling Stockholders
  3
  Plan of Distribution
  5
  Legal Matters
  7
  Experts
  7
  Incorporation of Certain Documents by Reference
  7
  Disclosure of Commission Position on Indemnification For Securities Act Liabilities
  8
  Additional Information Available to You
  8
  NO PERSON HAS BEEN AUTHORIZED TO GIVE ANY INFORMATION
  OR TO MAKE ANY REPRESENTATIONS, OTHER THAN THOSE CONTAINED IN THIS REOFFER PROSPECTUS, IN CONNECTION WITH THE OFFERING MADE HEREBY, AND,
  IF GIVEN OR MADE, SUCH INFORMATION OR REPRESENTATION MUST NOT BE RELIED UPON AS HAVING BEEN AUTHORIZED BY THE COMPANY OR ANY OTHER PERSON.
  NEITHER THE DELIVERY OF THIS REOFFER PROSPECTUS NOR ANY SALE MADE HEREUNDER SHALL UNDER ANY CIRCUMSTANCES CREATE ANY IMPLICATION THAT
  THERE HAS BEEN NO CHANGE IN THE AFFAIRS OF THE COMPANY SINCE THE DATE HEREOF. THIS REOFFER PROSPECTUS DOES NOT CONSTITUTE AN OFFER TO
  SELL OR A SOLICITATION OF AN OFFER TO BUY ANY SECURITIES OFFERED HEREBY BY ANYONE IN ANY JURISDICTION IN WHICH SUCH OFFER OR SOLICITATION
  IS NOT AUTHORIZED OR IN WHICH THE PERSON MAKING SUCH OFFER OR SOLICITATION IS NOT QUALIFIED TO DO SO OR TO ANY PERSON TO WHOM IT IS UNLAWFUL
  TO MAKE SUCH OFFER OR SOLICITATION.
  i
  CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
  Some of the statements made under "Prospectus Summary,"
  "Risk Factors," and elsewhere in this reoffer prospectus, as well as the documents incorporated by reference herein, including
  in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, constitute forward-looking statements. In some cases, you
  can identify forward-looking statements by terminology such as "may," "will," "should," "expects,"
  "plans," "anticipates," "believes," "estimates," "predicts," "potential,"
  "intends," or "continue," or the negative of these terms or other comparable terminology.
  These forward-looking statements may include, but are not limited to,
  statements related to our expected business, new product introductions, results of clinical studies, expectations regarding regulatory
  clearance and the timing of U.S. Food and Drug Administration ("FDA") or non-U.S. filings or approvals including meetings
  with FDA or non-U.S. regulatory bodies, our ability to raise funds for general corporate purposes and operations, including our research
  activities and clinical trials, procedures and procedure adoption, future results of operations, future financial position, our ability
  to generate revenues, our financing plans and future capital requirements, anticipated costs of revenue, anticipated expenses, the effect
  of recent accounting pronouncements, our anticipated cash flows, our ability to finance operations from cash flows or otherwise, and statements
  based on current expectations, estimates, forecasts, and projections about the economies and markets in which we operate and intend to
  operate and our beliefs and assumptions regarding these economies and markets.
  Forward-looking statements are not guarantees of future performance
  and are subject to risks and uncertainties. We have based these forward-looking statements on assumptions and assessments made by our
  management in light of their experience and their perception of historical trends, current conditions, expected future developments, and
  other factors they believe to be appropriate.
  Important factors that could cause actual results, developments and
  business decisions to differ materially from those anticipated in these forward-looking statements include, among others, those factors
  referred to in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which is incorporated by reference herein.
  These statements are only current predictions and are subject to known
  and unknown risks, uncertainties, and other factors that may cause our or our industry's actual results, levels of activity, performance,
  or achievements to be materially different from those anticipated by the forward-looking statements. We discuss many of these risks in
  the documents incorporated by reference herein. You should not rely upon forward-looking statements as predictions of future events.
  Although we believe that the expectations reflected in the forward-looking
  statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements. Except as required by
  law, we are under no duty to update or revise any of the forward-looking statements, whether as a result of new information, future events
  or otherwise, after the date of this reoffer prospectus.
  ii
  PROSPECTUS SUMMARY
  This reoffer prospectus is part of the Registration Statement that
  we filed with the SEC. We have provided to you in this reoffer prospectus a general description of the selling stockholders and the distribution
  of the shares of common stock. To the extent there is a conflict between the information contained in this reoffer prospectus and any
  of our subsequent filings with the SEC, the information in the document having the later date shall modify or supersede the earlier statement.
  As permitted by the rules and regulations of the SEC, the Registration
  Statement of which this reoffer prospectus forms a part includes additional information not contained in this reoffer prospectus. You
  may read the Registration Statement and the other reports we file with the SEC at the SEC's website or at our website as described
  above under the heading "Incorporation of Certain Documents by Reference."
  In this reoffer prospectus, the "Company," "we,"
  "us" and "our" refer to INmune Bio Inc. and its subsidiaries.
  Company Overview
  Our objective is to develop and commercialize our product candidates
  to treat diseases where the innate immune system is dysfunctional causing or contributing to the patient's disease. Innate immune
  dysfunction can occur for a variety of reasons including genetics, lifestyle, and other factors. However, age plays a significant role
  in the development of immune dysfunction. Innate immune dysfunction can be seen in cancer where natural killer cells are impaired and
  facilitate a tumor's evasion of the immune system and subsequent disease progression. Chronic inflammation is implicated in neurologic
  and metabolic diseases where it impairs the innate immune system. Our primary focus continues to be treatment of cancer with INKmune and
  treatment of Alzheimer's Disease ("AD") and Treatment Resistant Depression ("TRD") with XPro1595 ("XPro").
  We have added CORDStrom, a pooled, human umbilical cord mesenchymal stem cell product to treat recessive dystrophic epidermolysis bullosa
  ("RDEB"), a pediatric orphan disease caused by mutations in the COL7A1 gene that results in a debilitating disease of skin
  blistering, dysphagia and failure to thrive with chronic wound problems that often results in fatal squamous cell carcinoma.
  XPro, targets AD and TRD. XPro for AD has completed Phase I trials
  and a Phase II trial has completed enrollment of patients at clinical sites in the United Kingdom, European Union ("EU"),
  Australia and Canada. Patients are currently being treated with XPro for early AD as part of that clinical trial. TRD is being prepared
  for Phase II trials. We expect to start a pivotal global registration trial in patients with AD after the results of the Phase II trial
  have been analyzed. The INKmune program is in an open label Phase II trial in metastatic castrate resistant prostate cancer. CORDStrom
  for the treatment of children with RDEB has completed a pivotal blinded randomized cross-over trial. The data will be submitted for a
  marketing authorization by filing a biologics license application with the FDA which is anticipated in the first half of 2026. Afterwards,
  the company intends to file a marketing authorization application in the United Kingdom and EU.
  Corporate Information
  Our principal executive offices are located at 225 NE Mizner Blvd.,
  Suite 640, Boca Raton, Florida 33432. Our telephone number is (561) 710-0512. We maintain an Internet website at www.inmunebio.com. The
  information contained on, connected to or that can be accessed via our website is not part of this reoffer prospectus and should not be
  relied upon in connection with making any decision with respect to an investment in our securities. We are required to file annual, quarterly
  and current reports, proxy statements and other information with the SEC. You may obtain any of the documents filed by us with the SEC
  at no cost from the SEC's website at http://www.sec.gov.
  About This Offering
  This offering relates to the resale by the selling stockholders of
  up to 1,592,000 and 1,732,550 shares of common stock issued or issuable upon exercise of options issued pursuant to grants made pursuant
  to our 2017 Plan and 2019 Plan, respectively. If, subsequent to the date of this reoffer prospectus, we grant additional shares of common
  stock to the selling stockholders or to other affiliates under the 2017 Plan and 2019 Plan, we may supplement this reoffer prospectus
  to reflect such additional shares to the selling stockholders and/or the names of such affiliates and the number of shares to be reoffered
  by them under the 2017 Plan and 2019 Plan. Subject to the satisfaction of any conditions to vesting of the shares of common stock offered
  hereby pursuant to the terms of the relevant award agreements, the selling stockholders may from time to time sell, transfer or otherwise
  dispose of any or all of the shares of common stock covered by this reoffer prospectus through underwriters or dealers, directly to purchasers
  (or a single purchaser) or through broker-dealers or agents. We will not receive any proceeds from the sale of common stock by the selling
  stockholders. The selling stockholders will bear all sales commissions and similar expenses. We will bear all expenses of registration
  incurred in connection with this offering, including any other expenses incurred by us in connection with the registration and offering
  that are not borne by the selling stockholders.
  1
  RISK FACTORS
  Investing in our securities involves a high degree
  of risk. Before making an investment decision, you should consider carefully the risks, uncertainties and other factors described in our
  most recently filed Annual Report on Form 10-K, our subsequent quarterly reports on Form 10-Q and current reports on Form 8-K that we
  have filed or will file with the SEC.
  Our business, prospects,
  financial condition, or operating results could be harmed by any of these risks, as well as other risks not currently known to us or that
  we currently consider immaterial. The trading price of our common stock could decline due to any of these risks, and, as a result, you
  may lose all or part of your investment. The risks we have described also include forward-looking statements, and our actual results may
  differ substantially from those discussed in these forward-looking statements. See "
  Cautionary Note Regarding Forward-Looking
  Statements
  ."
  2
  DETERMINATION OF OFFERING
  PRICE
  The selling stockholders
  will determine at what price they may sell the shares of common stock offered hereby, and such sales may be made at prevailing market
  prices or at privately negotiated prices. See "
  Plan of Distribution
  " below for more information.
  USE OF PROCEEDS
  The shares of common stock offered
  hereby are being registered for the account of the selling stockholders named in this reoffer prospectus. All proceeds from the resale
  of the shares of common stock by the selling stockholders will go to the selling stockholders and we will not receive any proceeds from
  such resale. However, we will receive the cash exercise price if any of the selling stockholders exercise their options for common stock
  on a cash basis. We intend to use the net proceeds, if any, for working capital or general corporate purposes. We have agreed to pay the
  expenses of registration of these shares.
  SELLING STOCKHOLDERS
  This offering
  relates to the resale by the selling stockholders who have received or acquired, or may hereafter receive or acquire, the shares pursuant
  to the
  2017 Plan and 2019 Plan
  . The selling stockholders may resell all, a portion, or none
  of the shares of common stock from time to time.
  The following table sets forth, based on information
  provided to us by the selling stockholders or known to us, the name of each selling stockholder, the nature of any position, office or
  other material relationship, if any, which the selling stockholder has had, within the past three years, with us or with any of our predecessors
  or affiliates, and the number of shares of our common stock beneficially owned by the selling stockholder before this offering. Except
  as otherwise indicated, the selling stockholders are past or present employees, directors or consultants of the Company. The number of
  shares owned are those beneficially owned, as determined under the rules of the SEC, and the information is not necessarily indicative
  of beneficial ownership for any other purpose. Under these rules, beneficial ownership includes any shares of common stock as to
  which a person has sole or shared voting power or investment power and any shares of common stock which the person has the right to acquire
  within 60 days through the exercise of any option, warrant or right, through conversion of any security or pursuant to the automatic termination
  of a power of attorney or revocation of a trust, discretionary account or similar arrangement. None of the selling stockholders is a broker-dealer
  or an affiliate of a broker-dealer. Percentage of ownership is based on 23,379,796 shares of common stock outstanding on May 31, 2025.
  We have assumed all shares of common stock reflected
  on the table will be sold from time to time in the offering covered by this reoffer prospectus. Because the selling stockholders
  may offer all or any portion of the shares of common stock listed in the table below, no estimate can be given as to the amount of those
  shares of common stock covered by this reoffer prospectus that will actually be held by the selling stockholders upon the termination
  of the offering. Selling stockholders may choose not to sell any of the shares of common stock registered herein.
  3
  Number
  of Shares
  Beneficially Owned Prior
  to Offering (1)
  Number of
  Shares
  Being
  Number of Shares
  Beneficially Owned After
  Offering
  Selling Stockholder
  Position
  Number
  Percent (%)
  Offered
  Number
  Percent (%)
  Raymond J. Tesi
  President, CEO and Director
  2,730,952
  11.1
  %
  729,337
  (2)
  2,001,615
  8.4
  %
  David Moss
  CFO, Treasurer and Secretary
  2,422,143
  9.9
  %
  734,337
  (3)
  1,687,806
  7.1
  %
  Mark Lowdell
  CSO
  2,238,396
  9.3
  %
  580,000
  (4)
  1,658,396
  7.0
  %
  Scott Juda
  Director
  427,900
  1.8
  %
  231,975
  (5)
  195,925
  *
  Timothy Schroeder
  Director
  408,881
  1.7
  %
  231,975
  (6)
  176,906
  *
  J. Kelly Ganjei
  Director
  344,487
  1.5
  %
  231,975
  (7)
  112,512
  *
  Marcia Allen
  Director
  218,694
  *
  139,951
  (8)
  81,850
  *
  Named Selling Stockholders
  1,211,346
  5.1
  %
  445,000
  (9)
  766,346
  3.2
  %
  Total
  10,002,799
  3,324,550
  6,681,356
  *
  Less than 1%
  (1)
  The securities "beneficially owned" by a person
  are determined in accordance with the definition of "beneficial ownership" set forth in the rules and regulations promulgated
  under the Exchange Act, and accordingly, may include securities owned by and for, among others, the spouse and/or minor children of an
  individual and any other relative who has the same home as such individual, as well as other securities as to which the individual has
  or shares voting or investment power or which such person has the right to acquire within 60 days of May 31, 2025, pursuant to the exercise
  of options, or otherwise. Beneficial ownership may be disclaimed as to certain of the securities.
  (2)
  Includes: (a) vested options to purchase 400,000 shares of
  common stock exercisable by Mr. Tesi at an exercise price of $7.80 per share pursuant to the 2017 Plan; (b) vested options to purchase
  270,000 shares of common stock exercisable by Mr. Tesi at an exercise price of $3.91 per share pursuant to the 2019 Plan; and (c) vested
  options to purchase 59,337 shares of common stock exercisable by Mr. Tesi at an exercise price of $24.82 per share pursuant to the 2019
  Plan.
  (3)
  Includes: (a) vested options to purchase 400,000 shares of
  common stock exercisable by Mr. Moss at an exercise price of $7.80 per share pursuant to the 2017 Plan; (b) vested options to purchase
  59,337 shares of common stock exercisable by Mr. Moss at an exercise price of $24.82 per share pursuant to the 2017 Plan; and (c) vested
  options to purchase 275,000 shares of common stock exercisable by Mr. Moss at an exercise price of $3.91 per share pursuant to the 2019
  Plan.
  (4)
  Includes: (a) vested options to purchase 400,000 shares of
  common stock exercisable by Mr. Lowdell at an exercise price of $7.80 per share pursuant to the 2017 Plan; and (b) vested options to
  purchase 180,000 shares of common stock exercisable by Mr. Lowdell at an exercise price of $3.91 per share pursuant to the 2019 Plan.
  (5)
  Includes (a) vested options to purchase 108,000 shares of
  common stock exercisable by Mr. Juda at an exercise price of $7.80 per share pursuant to the 2017 Plan; (b) vested options to purchase
  108,000 shares of common stock exercisable by Mr. Juda at an exercise price of $3.91 per share pursuant to the 2019 Plan; and (c) vested
  options to purchase 15,975 shares of common stock exercisable by Mr. Juda at an exercise price of $24.82 per share pursuant to the 2019
  Plan.
  (6)
  Includes: (a) vested options to purchase 108,000 shares of
  common stock exercisable by Mr. Schroeder at an exercise price of $7.80 per share pursuant to the 2017 Plan; (b) vested options to purchase
  108,000 shares of common stock exercisable by Mr. Schroeder at an exercise price of $3.91 per share pursuant to the 2019 Plan; and (c)
  vested options to purchase 15,975 shares of common stock exercisable by Mr. Schroeder at an exercise price of $24.82 per share pursuant
  to the 2019 Plan.
  (7)
  Includes: (a) vested options to purchase 108,000 shares of
  common stock exercisable by Mr. Ganjei at an exercise price of $7.80 per share pursuant to the 2017 Plan; (b) vested options to purchase
  108,000 shares of common stock exercisable by Mr. Ganjei at an exercise price of $3.91 per share pursuant to the 2019 Plan; and (c) vested
  options to purchase 15,975 shares of common stock exercisable by Mr. Ganjei at an exercise price of $24.82 per share pursuant to the
  2019 Plan.
  (8)
  Includes: (a) vested options to purchase 108,000 shares of common stock exercisable by Mrs. Allen at
                                                      an exercise price of $3.91 per share pursuant to the 2019 Plan; (b) vested options to purchase 15,975 shares of common stock
                                                      exercisable by Mrs. Allen at an exercise price of $24.82 per share pursuant to the 2019 Plan; (c) options to purchase 7,313 shares
                                                      of common stock exercisable by Mrs. Allen at an exercise price of $9.74 per share pursuant to the 2019 Plan of which 5,891 are
                                                      exercisable; and (d) options to purchase 8,663 shares of common stock exercisable by Mrs. Allen at an exercise price of $9.74
                                                      pursuant to the 2017 Plan, of which 6,978 are exercisable.
  (9)
  Includes the following 3 named non-affiliate persons, each of whom
  holds at least 1,000 Shares of Class A common stock or equity awards issuable for an amount equal to 1% or more of the securities
  issuable pursuant to the Company's 2017 and 2019 Stock Option Plans: Christopher Barnum, Josh Schoonover and Cory Ellspermann.
  4
  PLAN OF DISTRIBUTION
  Timing of Sales
  The selling
  stockholders may offer and sell the shares covered by this reoffer prospectus at various times. The selling stockholders will act independently
  of our company in making decisions with respect to the timing, manner and size of each sale.
  To our knowledge, no selling stockholder has any
  agreement or understanding, directly or indirectly, with any person to resell the shares of common stock covered by this reoffer prospectus.
  Offering Price
  The sales price offered by the selling stockholders
  to the public may be:
  1.
  the
  market price prevailing at the time of sale;
  2.
  a
  price related to such prevailing market price; or
  3.
  such
  other price as the selling stockholders determine from time to time.
  Manner of Sale
  The shares of common stock may be sold by means
  of one or more of the following methods:
  1.
  a
  block trade in which the broker-dealer so engaged will attempt to sell the shares of common stock as agent, but may position and resell
  a portion of the block as principal to facilitate the transaction;
  2.
  purchases
  by a broker-dealer as principal and resale by that broker-dealer for its account pursuant to this reoffer prospectus;
  3.
  ordinary
  brokerage transactions in which the broker solicits purchasers;
  4.
  through
  options, swaps or derivatives;
  5.
  in
  transactions to cover short sales;
  6.
  privately
  negotiated transactions; or
  7.
  in
  a combination of any of the above methods.
  The selling stockholders may sell their shares
  of common stock directly to purchasers or may use brokers, dealers, underwriters or agents to sell their shares of common stock. Brokers
  or dealers engaged by the selling stockholders may arrange for other brokers or dealers to participate. Brokers or dealers may receive
  commissions, discounts or concessions from the selling stockholders, or, if any such broker-dealer acts as agent for the purchaser of
  shares of common stock, from the purchaser in amounts to be negotiated immediately prior to the sale. The compensation received by brokers
  or dealers may, but is not expected to, exceed that which is customary for the types of transactions involved.
  Broker-dealers may agree with a selling stockholder
  to sell a specified number of shares of common stock at a stipulated price per common share, and, to the extent the broker-dealer is unable
  to do so acting as agent for a selling stockholder, to purchase as principal any unsold shares of common stock at the price required to
  fulfill the broker-dealer commitment to the selling stockholder.
  5
  Broker-dealers who acquire shares of common stock
  as principal may thereafter resell the shares of common stock from time to time in transactions, which may involve block transactions
  and sales to and through other broker-dealers, including transactions of the nature described above, on the Nasdaq Capital Market or otherwise
  at prices and on terms then prevailing at the time of sale, at prices then related to the then-current market price or in negotiated transactions.
  In connection with resales of the shares of common stock, broker-dealers may pay to or receive from the purchasers of shares commissions
  as described above.
  If the selling stockholders enter into arrangements
  with brokers or dealers, as described above, we are obligated to file a post-effective amendment to this registration statement disclosing
  such arrangements, including the names of any broker-dealers acting as underwriters.
  The selling stockholders and any broker-dealers
  or agents that participate with the selling stockholders in the sale of the shares of common stock may be deemed to be "underwriters"
  within the meaning of the Securities Act. In that event, any commissions received by broker-dealers or agents and any profit on the resale
  of the shares of common stock purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act.
  Sales Pursuant to Rule 144
  Any shares of common stock covered by this reoffer
  prospectus which qualify for sale pursuant to Rule 144 under the Securities Act may be sold under Rule 144 rather than pursuant to this
  reoffer prospectus.
  Regulation M
  The selling stockholders must comply with the
  requirements of the Securities Act and the Securities Exchange Act of 1934, as amended (the "Exchange Act") in the offer and
  sale of the common stock. In particular we will advise the selling stockholders that the anti-manipulation rules of Regulation M
  under the Exchange Act may apply to sales of shares of common stock in the market and to the activities of the selling stockholders and
  their affiliates. Regulation M under the Exchange Act prohibits, with certain exceptions, participants in a distribution from bidding
  for, or purchasing for an account in which the participant has a beneficial interest, any of the securities that are the subject of the
  distribution.
  Accordingly, during such times as a selling stockholder
  may be deemed to be engaged in a distribution of the common stock, and therefore be considered to be an underwriter, the selling stockholder
  must comply with applicable law and, among other things:
  1.
  may not engage in any stabilization activities in connection with our common stock;
  2.
  may not cover short sales by purchasing shares while the distribution is taking place; and
  3.
  may not bid for or purchase any of our securities or attempt to induce any person to purchase any of our securities other than as permitted under the Exchange Act.
  In addition, we will make copies of this reoffer
  prospectus available to the selling stockholders for the purpose of satisfying the reoffer prospectus delivery requirements of the Securities
  Act.
  State Securities Laws
  Under the securities laws of some states, the
  shares of common stock may be sold in such states only through registered or licensed brokers or dealers. In addition, in some states
  the shares of common stock may not be sold unless the shares have been registered or qualified for sale in the state or an exemption from
  registration or qualification is available and is complied with.
  Expenses of Registration
  We are bearing all costs relating to the registration
  of the common stock. The selling stockholders, however, will pay any commissions or other fees payable to brokers or dealers in connection
  with any sale of the common stock.
  6
  LEGAL MATTERS
  The validity of the common stock has been passed
  upon by Sichenzia Ross Ference Carmel LLP, New York, New York.
  EXPERTS
  The consolidated financial statements of INmune
  Bio Inc. as of and for the years ended December 31, 2024 and 2023 appearing in INmune Bio Inc.'s Annual Report on Form 10-K for
  the year ended December 31, 2024, have been audited by Marcum LLP, as set forth in its report thereon, included therein, and incorporated
  herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance upon such report given on
  the authority of such firm as experts in accounting and auditing.
  INCORPORATION
  OF CERTAIN DOCUMENTS by Reference
  The SEC, allows us to incorporate by reference
  certain of our publicly filed documents into this reoffer prospectus, which means that such information is considered part of this reoffer
  prospectus. Information that we file with the SEC subsequent to the date of this reoffer prospectus will automatically update and supersede
  this information. We incorporate by reference the documents listed below and any future filings made with the SEC under all documents
  subsequently filed by us pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act until the selling stockholders have sold all
  of the shares offered hereby or such shares have been deregistered.
  ●
  Our
  Annual Report on
  Form
  10-K
  for the year ended December 31, 2024, filed
  with the SEC on March 27, 2025;
  ●
  Our
  Quarterly Report on
  Form
  10-Q
  for the quarter ended March 31, 2025, filed
  with the SEC on
  May
  8, 2025
  ;
  ●
  Our
  Definitive Proxy Statement on Schedule 14A filed with the SEC on
  April
  21, 2025
  , as supplemented on
  April
  25, 2025
  , and as amended on
  May
  9, 2025
  , respectively;
  ●
  our
  Current Reports on Form 8-K (other than information furnished rather than filed) filed with the SEC on
  January
  28, 2025
  ,
  February
  10, 2025
  ,
  February
  12, 2025
  ,
  March
  24, 2025
  ,
  April
  1, 2025
  ,
  April
  14, 2025
  ,
  May
  5, 2025
  ,
  May
  7, 2025,
  May
  14, 2025
  and
  June 10, 2025
  and
  ●
  The
  description of our common stock contained in our Registration Statement on
  Form
  8-A
  filed with the SEC on February 1, 2019 (File
  No. 001-38793), including any amendment or report filed for the purpose of updating such description. In addition, a
  Form
  8-A
  filed on December 30, 2020, contains a description
  of certain rights attributable to the common stock.
  Notwithstanding the foregoing, information furnished
  under Items 2.02 and 7.01 of any Current Report on Form 8-K, including the related exhibits, is not incorporated by reference in this
  Registration Statement. The information about us contained in this reoffer prospectus should be read together with the information in
  the documents incorporated by reference. You may request a copy of any or all of these filings, at no cost, by writing or telephoning
  us at: David Moss, INmune Bio Inc., 225 NE Mizner Blvd, Suite 640, Boca Raton, Florida 33432, telephone number (561) 710-0512.
  7
  Disclosure Of Commission Position On Indemnification For
  Securities Act Liabilities
  NRS 78.7502(1) provides that a corporation may
  indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or
  proceeding, whether civil, criminal, administrative or investigative, except an action by or in the right of the corporation, by reason
  of the fact that he is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation
  as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses,
  including attorneys' fees, judgments, fines and amounts paid in settlement actually and reasonably incurred by him in connection
  with the action, suit or proceeding if he: (a) is not liable pursuant to NRS 78.138; or (b) acted in good faith and in a manner which
  he reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding,
  had no reasonable cause to believe his conduct was unlawful.
  NRS Section 78.7502(2) provides that a corporation
  may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit
  by or in the right of the corporation to procure a judgment in its favor by reason of the fact that he is or was a director, officer,
  employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent
  of another corporation, partnership, joint venture, trust or other enterprise against expenses, including amounts paid in settlement and
  attorneys' fees actually and reasonably incurred by him in connection with the defense or settlement of the action or suit if he:
  (a) is not liable pursuant to NRS 78.138; or (b) acted in good faith and in a manner which he reasonably believed to be in or not opposed
  to the best interests of the corporation. Indemnification may not be made for any claim, issue or matter as to which such a person has
  been adjudged by a court of competent jurisdiction, after exhaustion of all appeals there from, to be liable to the corporation or for
  amounts paid in settlement to the corporation, unless and only to the extent that the court in which the action or suit was brought or
  other court of competent jurisdiction determines upon application that in view of all the circumstances of the case, the person is fairly
  and reasonably entitled to indemnity for such expenses as the court deems proper.
  Our Articles of Incorporation provides that every
  person who was or is a party to, or is threatened to be made a party to, or is involved in any action, suit or proceeding, whether civil,
  criminal, administrative or investigative, by reason of the fact that he, or a person of whom he is the legal representative, is or was
  a director or officer of the Company, or is or was serving at the request of the Company as a director or officer of another corporation,
  or as its representative in a partnership, joint venture, trust or other enterprise, shall be indemnified and held harmless to the fullest
  extent legally permissible under the laws of the State of Nevada from time to time against all expenses, liability and loss (including
  attorney's fees, judgements, fines and amounts paid or to be paid in settlement) reasonably incurred or suffered by him in connection
  therewith. Such right of indemnification shall be a contract right which may be enforced in any matter desired by such person. The expenses
  of the officers and directors incurred in defending a civil or criminal action, suit or proceeding must be paid by the Company as they
  are incurred and in advance of the final disposition of the action, suit or proceeding, upon receipt of an undertaking by or on behalf
  of the director or officer to repay the amount if it is ultimately determined by a court of competent jurisdiction that he is not entitled
  to be indemnified by the Company. Such right of indemnification shall not be exclusive of any other right which such directors, officers
  or representatives may have or hereafter acquire, and, without limiting the generality of such statement, they shall be entitled to their
  respective rights of indemnification under any bylaw, agreement, vote of stockholders, provision of law, or otherwise, as well as their
  rights under this Article.
  NRS Section 78.747 provides that except as otherwise
  provided by specific statute, no director or officer of a corporation is individually liable for a debt or liability of the corporation,
  unless the director or officer acts as the alter ego of the corporation. The court as a matter of law must determine the question of whether
  a director or officer acts as the alter ego of a corporation.
  Insofar as indemnification for liabilities arising
  under the Securities Act may be permitted to directors, offices or controlling persons of ours, pursuant to the foregoing provisions,
  or otherwise, we have been advised that, in the opinion of the Securities and Exchange Commission, such indemnification is against public
  policy as expressed in the Securities Act, and is, therefore, unenforceable. In the event that a claim for indemnification against such
  liabilities (other than the payment by us of expenses incurred or paid by a director, officer or controlling person of ours in the successful
  defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities
  being registered hereunder, we will, unless in the opinion of our counsel the matter has been settled by controlling precedent, submit
  to a court of appropriate jurisdiction the question whether such indemnification by us is against public policy as expressed in the Securities
  Act and will be governed by the final adjudication of such issue.
  Additional Information Available to You
  This prospectus is part of a Registration Statement
  on Form S-8 that we filed with the SEC. Certain information in the Registration Statement has been omitted from this prospectus in accordance
  with the rules of the SEC. We file annual, quarterly and special reports, proxy statements and other information with the SEC. You can
  inspect and copy the Registration Statement as well as reports, proxy statements and other information we have filed with the SEC at the
  public reference room maintained by the SEC at 100 F Street N.E. Washington, D.C. 20549, You can obtain copies from the public reference
  room of the SEC at 100 F Street N.E. Washington, D.C. 20549, upon payment of certain fees. You can call the SEC at 1-800-732-0330 for
  further information about the public reference room. We are also required to file electronic versions of these documents with the SEC,
  which may be accessed through the SEC's World Wide Web site at http://www.sec.gov. No dealer, salesperson or other person is authorized
  to give any information or to make any representations other than those contained in this prospectus, and, if given or made, such information
  or representations must not be relied upon as having been authorized by us. This prospectus does not constitute an offer to buy any security
  other than the securities offered by this prospectus, or an offer to sell or a solicitation of an offer to buy any securities by any person
  in any jurisdiction where such offer or solicitation is not authorized or is unlawful. Neither delivery of this prospectus nor any sale
  hereunder shall, under any circumstances, create any implication that there has been no change in the affairs of our company since the
  date hereof.
  8
  PART II
  INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
  Item 3. Incorporation of Documents by Reference.
  The Securities and Exchange Commission, or SEC,
  allows us to incorporate by reference certain of our publicly filed documents into this prospectus, which means that such information
  is considered part of this prospectus. Information that we file with the SEC subsequent to the date of this prospectus will automatically
  update and supersede this information. We incorporate by reference the documents listed below and any future filings made with the SEC
  under all documents subsequently filed by us pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act until the selling stockholders
  have sold all of the shares offered hereby or such shares have been deregistered.
  ●
  Our
  Annual Report on
  Form
  10-K
  for the year ended December 31, 2024, filed
  with the SEC on March 27, 2025;
  ●
  Our
  Quarterly Report on
  Form
  10-Q
  for the quarter ended March 31, 2025, filed
  with the SEC on
  May
  8, 2025
  ;
  ●
  Our
  Definitive Proxy Statement on Schedule 14A filed with the SEC on
  April
  21, 2025
  , as supplemented on
  April
  25, 2025
  , and as amended on
  May
  9, 2025
  , respectively;
  ●
  our
  Current Reports on Form 8-K (other than information furnished rather than filed) filed with the SEC on
  January
  28, 2025
  ,
  February
  10, 2025
  ,
  February
  12, 2025
  ,
  March
  24, 2025
  ,
  April
  1, 2025
  ,
  April
  14, 2025
  ,
  May
  5, 2025
  ,
  May
  7, 2025,
  May
  14, 2025
  and
  June 10, 2025
  and
  ●
  The
  description of our common stock contained in our Registration Statement on
  Form
  8-A
  filed with the SEC on February 1, 2019 (File
  No. 001-38793), including any amendment or report filed for the purpose of updating such description. In addition, a
  Form
  8-A
  filed on December 30, 2020, contains a description
  of certain rights attributable to the common stock.
  Notwithstanding the foregoing, information furnished under Items 2.02
  and 7.01 of any Current Report on Form 8-K, including the related exhibits, is not incorporated by reference in this Registration Statement.
  The information about us contained in this reoffer prospectus should be read together with the information in the documents incorporated
  by reference. You may request a copy of any or all of these filings, at no cost, by writing or telephoning us at: David Moss, INmune Bio
  Inc., 225 NE Mizner Blvd, Suite 640, Boca Raton, Florida 33432, telephone number (561) 710-0512.
  Item 4. Description of Securities.
  Not applicable.
  Item 5. Interests of Named Experts and Counsel.
  None.
  Item 6. Indemnification of Directors and Officers.
  Section 78.7502(1) of the Nevada Revised Statutes ("NRS")
  provides that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending
  or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, except an action by or in the right
  of the corporation, by reason of the fact that he is or was a director, officer, employee or agent of the corporation, or is or was serving
  at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust
  or other enterprise, against expenses, including attorneys' fees, judgments, fines and amounts paid in settlement actually and reasonably
  incurred by him in connection with the action, suit or proceeding if he: (a) is not liable pursuant to NRS 78.138; or (b) acted in good
  faith and in a manner which he reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect
  to any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful.
  II-
  1
  NRS Section 78.7502(2) provides that a corporation may indemnify any
  person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right
  of the corporation to procure a judgment in its favor by reason of the fact that he is or was a director, officer, employee or agent of
  the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation,
  partnership, joint venture, trust or other enterprise against expenses, including amounts paid in settlement and attorneys' fees
  actually and reasonably incurred by him in connection with the defense or settlement of the action or suit if he: (a) is not liable pursuant
  to NRS 78.138; or (b) acted in good faith and in a manner which he reasonably believed to be in or not opposed to the best interests of
  the corporation. Indemnification may not be made for any claim, issue or matter as to which such a person has been adjudged by a court
  of competent jurisdiction, after exhaustion of all appeals there from, to be liable to the corporation or for amounts paid in settlement
  to the corporation, unless and only to the extent that the court in which the action or suit was brought or other court of competent jurisdiction
  determines upon application that in view of all the circumstances of the case, the person is fairly and reasonably entitled to indemnity
  for such expenses as the court deems proper.
  Our Articles of Incorporation provides that very person who was or
  is a party to, or is threatened to be made a party to, or is involved in any action, suit or proceeding, whether civil, criminal, administrative
  or investigative, by reason of the fact that he, or a person of whom he is the legal representative, is or was a director or officer of
  the Company, or is or was serving at the request of the Company as a director or officer of another corporation, or as its representative
  in a partnership, joint venture, trust or other enterprise, shall be indemnified and held harmless to the fullest extent legally permissible
  under the laws of the State of Nevada from time to time against all expenses, liability and loss (including attorney's fees, judgements,
  fines and amounts paid or to be paid in settlement) reasonably incurred or suffered by him in connection therewith. Such right of indemnification
  shall be a contract right which may be enforced in any matter desired by such person. The expenses of the officers and directors incurred
  in defending a civil or criminal action, suit or proceeding must be paid by the Company as they are incurred and in advance of the final
  disposition of the action, suit or proceeding, upon receipt of an undertaking by or on behalf of the director or officer to repay the
  amount if it is ultimately determined by a court of competent jurisdiction that he is not entitled to be indemnified by the Company. Such
  right of indemnification shall not be exclusive of any other right which such directors, officers or representatives may have or hereafter
  acquire, and, without limiting the generality of such statement, they shall be entitled to their respective rights of indemnification
  under any bylaw, agreement, vote of stockholders, provision of law, or otherwise, as well as their rights under this Article.
  NRS Section 78.747 provides that except as otherwise provided by specific
  statute, no director or officer of a corporation is individually liable for a debt or liability of the corporation, unless the director
  or officer acts as the alter ego of the corporation. The court as a matter of law must determine the question of whether a director or
  officer acts as the alter ego of a corporation.
  Insofar as indemnification for liabilities arising under the Securities
  Act of 1933, as amended, may be permitted to directors, offices or controlling persons of ours, pursuant to the foregoing provisions,
  or otherwise, we have been advised that, in the opinion of the SEC, such indemnification is against public policy as expressed in the
  Securities Act of 1933, as amended, and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities
  (other than the payment by us of expenses incurred or paid by a director, officer or controlling person of ours in the successful defense
  of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being
  registered hereunder, we will, unless in the opinion of our counsel the matter has been settled by controlling precedent, submit to a
  court of appropriate jurisdiction the question whether such indemnification by us is against public policy as expressed in the Securities
  Act of 1933, as amended, and will be governed by the final adjudication of such issue.
  II-
  2
  Item 7. Exemption from Registration Claimed.
  Not applicable.
  Item 8. Exhibits.
  Exhibit Number
  Description
  4.1
  Articles of Incorporation (Incorporated by reference to Exhibit 3.1 to the Registration Statement on Form S-1 filed with the SEC on August 30, 2018).
  4.2
  Bylaws (Incorporated by reference to Exhibit 3.2 to the Registration Statement on Form S-1 filed with the SEC on August 30, 2018).
  4.3
  First Amendment to the Bylaws of INmune Bio Inc. (Incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed with the SEC on May 23, 2024).
  5.1
  Opinion of Sichenzia Ross Ference Carmel LLP*
  23.1
  Consent of Marcum LLP*
  23.2
  Consent of Sichenzia Ross Ference Carmel LLP (included in Exhibit 5.1)*
  24.1
  Power of Attorney (included on the signature page)*
  99.1
  INmune Bio Inc. 2017 Stock Incentive Plan (incorporated by reference to the Form S-8 filed with the SEC on March 3, 2022).
  99.2
  INmune Bio Inc. 2019 Stock Incentive Plan (incorporated by reference to the Form S-8 filed with the SEC on March 3, 2022).
  107
  Filing Fee Table*
  *
  Filed herewith.
  **
  Previously Filed.
  Item 9. Undertakings.
  (a)
  The
  Company hereby undertakes:
  (1)
  To
  file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:
  (i)
  To
  include any prospectus required by Section 10(a)(3) of the Securities Act.
  (ii)
  To
  reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective
  amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration
  Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities
  offered  would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering
  range may be reflected in the form of prospectus filed with the Securities and Exchange Commission pursuant to Rule 424(b) if, in the
  aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth
  in the "Calculation of Registration Fee" table in the effective Registration Statement.
  (iii)
  To
  include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any
  material change to such information in the Registration Statement; provided, however, that (A) paragraphs (a)(1)(i) and (a)(1)(ii)
  of this section do not apply if the Registration Statement is on Form S–8 (§239.16b of Regulation S-K), and the information
  required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Securities
  and Exchange Commission by the Company pursuant to section 13 or section 15(d) of the Exchange Act (15 U.S.C. 78m or 78o(d)) that are
  incorporated by reference in the Registration Statement; and (B) paragraphs (a)(1)(i), (a)(1)(ii) and (a)(1)(iii) do not apply if
  the Registration Statement is on Form S-3 or Form F-3, and the information required to be included in a post-effective amendment by those
  paragraphs is contained in reports filed with or furnished to the Securities and Exchange Commission by the Company pursuant to Section 13
  or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement, or is contained in a form
  of prospectus filed pursuant to Rule 424(b) that is part of the Registration Statement; provided further, however, that paragraphs (a)(1)(i)
  and (a)(1)(ii) do not apply if the Registration Statement is for an offering of asset-backed securities on Form S-1 or Form S-3, and
  the information required to be included in a post-effective amendment is provided pursuant to Item 1100(c) of Regulation AB.
  II-
  3
  (2)
  That,
  for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new
  registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to
  be the initial bona fide offering thereof.
  (3)
  To
  remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination
  of the offering.
  (4)
  That,
  for the purpose of determining liability under the Securities Act of 1933 to any purchaser:
  (A) Each prospectus filed
  by a Registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus
  was deemed part of and included in the registration statement; and
  (B) Each prospectus required
  to be filed pursuant to Rule 424(b)(2), (b)(5) or (b)(7) as part of a registration statement in reliance on Rule 430B relating
  to an offering made pursuant to Rule 415(a)(1)(i),  (vii) or (x) for the purpose of providing the information
  required by Section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement as of
  the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities
  in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is
  at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities
  in the registration statement to which the prospectus relates, and the offering of such securities at that time shall be deemed to be
  the initial bona fide offering thereof. Provided, however, that no statement made in a registration statement or prospectus that is part
  of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or
  prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective
  date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement
  or made in any such document immediately prior to such effective date.
  (b)
  The
  Company hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Company's
  annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act that is incorporated by reference in this Registration
  Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities
  at that time shall be deemed to be the initial bona fide offering thereof.
  (c)
  Insofar
  as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of
  the Company pursuant to the foregoing provisions, or otherwise, the Company has been advised that in the opinion of the Securities and
  Exchange Commission such indemnification is against public policy as expressed in the Securities Act, and is, therefore, unenforceable.
  In the event that a claim for indemnification against such liabilities (other than the payment by the Company of expenses incurred or
  paid by a director, officer or controlling person of the Company in the successful defense of any action, suit or proceeding) is asserted
  by such director, officer or controlling person in connection with the securities being registered, the Company will, unless in the opinion
  of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether
  such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication
  of such issue.
  II-
  4
  SIGNATURES
  Pursuant
  to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that
  it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by
  the undersigned, thereunto duly authorized, in the City of Boca Raton, State of Florida, on June 13, 2025.
  INmune Bio Inc.
  /s/ Raymond J. Tesi
  Raymond J. Tesi, M. D.
  Chief Executive Officer
  (Principal Executive Officer)
  /s/ David J. Moss
  David J. Moss
  Chief Financial Officer
  (Principal Financial and Accounting Officer)
  II-
  5
  Each person whose signature
  appears below constitutes and appoints Raymond J. Tesi and David J. Moss, and each of them severally, as his true and lawful attorney
  in fact and agent, with full powers of substitution and re-substitution, for him and in his name, place and stead, in any and all capacities,
  to sign any or all amendments (including post effective amendments) to the Registration Statement, and to sign any registration statement
  for the same offering covered by this Registration Statement that is to be effective upon filing pursuant to Rule 462(b) under the Securities
  Act of 1933, as amended, and all post effective amendments thereto, and to file the same, with all exhibits thereto, and all documents
  in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent, each acting alone,
  full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises,
  as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact
  and agent, each acting alone, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
  Pursuant to the requirements
  of the Securities Act of 1933, as amended, this registration statement has been signed below by the following persons in the capacities
  and on the dates indicated.
  /s/ Raymond J. Tesi
  June 13, 2025
  Raymond J. Tesi, M.D.
  Chief Executive Officer and Director
  (principal executive officer)
  /s/ David J. Moss
  June 13, 2025
  David J. Moss
  Chief Financial Officer
  (principal financial and accounting officer)
  /s/ Timothy Schroeder
  June 13, 2025
  Timothy Schroeder
  Director
  /s/ J. Kelly Ganjei
  June 13, 2025
  J. Kelly Ganjei
  Director
  /s/ Scott Juda
  June 13, 2025
  Scott Juda, JD
  Director
  /s/ Marcia Allen
  June 13, 2025
  Marcia Allen
  Director
  II-6